Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
11-(ethylthio)-undecanoyl-CoA + glycylpeptide
11-(ethylthio)-undecanoyl-glycylpeptide + CoA
-
-
-
-
?
11-oxatetradecanoyl-CoA + G0alpha-hexapeptide
N-11-oxatetradecanoyl-G0alpha-hexapeptide + CoA
-
-
-
-
?
11-phenylundecanoyl-CoA + glycylpeptide
11-phenylundecanoyl-glycylpeptide + CoA
-
-
-
-
?
13-oxatetradecanoyl-CoA + G0alpha-hexapeptide
N-13-oxatetradecanoyl-G0alpha-hexapeptide + CoA
-
-
-
-
?
6-oxatetradecanoyl-CoA + G0alpha-hexapeptide
N-6-oxatetradecanoyl-G0alpha-hexapeptide + CoA
-
-
-
-
?
dodecanoyl-CoA + Gly-Asn-Ala-Ala-Ala-Ala-Arg-Arg
N-dodecanoyl-Gly-Asn-Ala-Ala-Ala-Ala-Arg-Arg + CoA
-
-
-
-
?
lauroyl-CoA + brain acid soluble protein 1
N-lauroyl-brain acid soluble protein 1 + CoA
-
-
N-laurylation of recombinant proteins in Escherichia coli may occur in minimal media
-
?
lauroyl-CoA + c-Src
N-lauroyl-c-Src + CoA
-
N-terminal region of c-Src, residues 1-185
N-laurylation of recombinant proteins in Escherichia coli may occur in minimal media
-
?
lauroyl-CoA + glycylpeptide
N-lauroylglycylpeptide + CoA
myristoleoyl-CoA + CAP5.5
N-myristoleoyl-CAP5.5 + CoA
myristoleoyl-CoA + glycylpeptide
N-myristoleoylglycylpeptide + CoA
-
-
-
-
?
myristoyl-CoA + Arabidopsis thaliana protein CDPK6-derived peptide
N-myristoylated Arabidopsis thaliana protein CDPK6-derived peptide + CoA
-
-
-
?
myristoyl-CoA + ARF peptide
CoA + N-myristoyl-ARF peptide
C-terminally biotinylated ARF peptide, i.e. GLYVSRLFNRLFQKK(Biotin)-NH2, substrate binding structures, overview
-
-
?
myristoyl-CoA + brain acid soluble protein 1
N-myristoyl-brain acid soluble protein 1 + CoA
-
-
-
-
?
myristoyl-CoA + c-Src
N-myristoyl-c-Src + CoA
-
N-terminal region of c-Src, residues 1-185
-
-
?
myristoyl-CoA + cAMP-dependent protein kinase-derived peptide
N-myristoylated cAMP-dependent protein kinase-derived peptide + CoA
myristoyl-CoA + CAP5.5 peptide
N-myristoylglycyl-CAP5.5 peptide + CoA
-
-
-
-
?
myristoyl-CoA + Fen kinase-derived peptide
N-myristoylated Fen kinase-derived peptide + CoA
plant protein peptide
-
-
?
myristoyl-CoA + GAQLSTLSRV
myristoylglycyl-AQLSTLSRV + CoA
-
-
-
?
myristoyl-CoA + GCGGSKVK
N-myristoylglycyl-CGGSKVK + CoA
-
-
-
?
myristoyl-CoA + GLTISKLFRR
?
-
-
-
?
myristoyl-CoA + GLTISKLFRR-NH2
?
-
-
-
?
myristoyl-CoA + Gly-Ala-Ala-Pro-Ser-Lys-Ile-Val
N-myristoyl-Gly-Ala-Ala-Pro-Ser-Lys-Ile-Val + CoA
-
-
-
?
myristoyl-CoA + Gly-Ala-Arg-Ala-Ala-Ala-Ala-Arg-Arg
N-myristoyl-Gly-Ala-Arg-Ala-Ala-Ala-Ala-Arg-Arg + CoA
-
-
-
-
?
myristoyl-CoA + Gly-Ala-Arg-Ala-Ser-Val-Leu-Ser
N-myristoyl-Gly-Ala-Arg-Ala-Ser-Val-Leu-Ser + CoA
-
-
-
-
?
myristoyl-CoA + Gly-Ala-Gln-Phe-Ser-Lys-Thr-Ala-Arg-Arg
N-myristoyl-Gly-Ala-Gln-Phe-Ser-Lys-Thr-Ala-Arg-Arg-derived peptide + CoA
-
i.e. myristolated alanine-rich C-kinase substrate MARCKS
-
-
?
myristoyl-CoA + Gly-Asn-Ala-Ala-Ala-Ala
N-myristoyl-Gly-Asn-Ala-Ala-Ala-Ala + CoA
-
-
-
-
?
myristoyl-CoA + Gly-Asn-Ala-Ala-Ala-Ala-Arg-Arg
N-myristoyl-Gly-Asn-Ala-Ala-Ala-Ala-Arg-Arg + CoA
myristoyl-CoA + Gly-Asn-Ala-Ala-Ala-Arg-Arg
N-myristoyl-Gly-Asn-Ala-Ala-Ala-Arg-Arg + CoA
-
-
-
-
?
myristoyl-CoA + Gly-Asn-Ala-Ala-Ser-Ala-Arg-Arg
N-myristoyl-Gly-Asn-Ala-Ala-Ser-Ala-Arg-Arg + CoA
myristoyl-CoA + Gly-Asn-Ala-Ala-Ser-Arg-Arg
N-myristoyl-Gly-Asn-Ala-Ala-Ser-Arg-Arg + CoA
-
-
-
-
?
myristoyl-CoA + Gly-Asn-Ala-Ala-Ser-Tyr-Arg-Arg
N-myristoyl-Gly-Asn-Ala-Ala-Ser-Tyr-Arg-Arg + CoA
myristoyl-CoA + Gly-Asn-Ala-Pro-Ala-Ala-Arg-Arg
N-myristoyl-Gly-Asn-Ala-Pro-Ala-Ala-Arg-Arg + CoA
-
-
-
-
?
myristoyl-CoA + Gly-Asn-Phe-Ala-Ala-Ala-Arg-Arg
N-myristoyl-Gly-Asn-Phe-Ala-Ala-Ala-Arg-Arg + CoA
-
-
-
-
?
myristoyl-CoA + Gly-Cys-Ser-Val-Ser-Lys-Lys-Lys
CoA + N-myristoyl-Gly-Cys-Ser-Val-Ser-Lys-Lys-Lys
-
-
-
?
myristoyl-CoA + Gly-Gln-Thr-Val-Thr-Thr-Pro-Leu
N-myristoyl-Gly-Gln-Thr-Val-Thr-Thr-Pro-Leu + CoA
-
-
-
-
?
myristoyl-CoA + Gly-L-Ala-L-Arg-L-Ala-L-Ser-L-Val-L-Leu-L-Ser
N-myristoyl-Gly-L-Ala-L-Arg-L-Ala-L-Ser-L-Val-L-Leu-L-Ser + CoA
-
-
-
-
?
myristoyl-CoA + Gly-Leu-Tyr-Ala-Ser-Lys-Leu-Ser
N-myristoyl-Gly-Leu-Tyr-Ala-Ser-Lys-Leu-Ser + CoA
-
-
-
-
?
myristoyl-CoA + Gly-Ser-Ser-Lys-Pro-Lys-Asp-Lys-Asp-Pro
N-myristoyl-Gly-Ser-Ser-Lys-Pro-Lys-Asp-Lys-Asp-Pro + CoA
-
-
-
-
?
myristoyl-CoA + Gly-Ser-Ser-Lys-Ser-Lys-Pro-Lys
N-myristoyl-Gly-Ser-Ser-Lys-Ser-Lys-Pro-Lys + CoA
-
-
-
-
?
myristoyl-CoA + Gly-Ser-Ser-Lys-Ser-Lys-Pro-Lys-Arg
N-myristoyl-Gly-Ser-Ser-Lys-Ser-Lys-Pro-Lys-Arg + CoA
myristoyl-CoA + Gly-Ser-Ser-Lys-Ser-Lys-Pro-Lys-Asp-Pro-Ser-Gln-Arg-Arg-Arg
N-myristoyl-Gly-Ser-Ser-Lys-Ser-Lys-Pro-Lys-Asp-Pro-Ser-Gln-Arg-Arg-Arg + CoA
-
pp60src-derived peptide
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
myristoyl-CoA + GNAASARR
?
-
-
-
?
myristoyl-CoA + GQLFTSLN
N-myristoylglycyl-GQLFTSLN + CoA
-
-
-
?
myristoyl-CoA + HBV preS1
? + CoA
-
N-myristoylation of HBV preS1 is essential for viral infectivity. HBV preS1 is a fusion protein of hepatitis B virus preS1 with the native-type N-terminus and a His6-Tag fused to C-terminus
-
-
?
myristoyl-CoA + HBV preS1-HT
? + CoA
-
fusion protein of hepatitis B virus preS1 with the native-type N-terminus and a His6-Tag fused to C-terminus
-
-
?
myristoyl-CoA + HIV-1 Nef protein
?
-
myristoylation results in conformational changes in HIV-1 Nef
-
-
?
myristoyl-CoA + HIV-1 negative regulatory factor
N-myristoyl-HIV-1 negative regulatory factor + CoA
-
-
-
?
myristoyl-CoA + HIV1 Gag protein N-terminal peptide
N-myristoyl-HIV1 Gag protein N-terminal peptide + CoA
-
-
-
?
myristoyl-CoA + HIV1 Nef protein N-terminal peptide
N-myristoyl-HIV1 Nef protein N-terminal peptide + CoA
-
-
-
?
myristoyl-CoA + M2 gene segment of reovirus type 3-derived peptide
N-myristoylated M2 gene segment of reovirus type 3-derived peptide + CoA
myristoyl-CoA + Nef
? + CoA
-
Nef forms a stable complex specifically with N-myristoyltransferase isoform 1. The association requires an Nterminal region of Nef containing an intact myristoylation signal and represents a transient intermediate of the myristoylation reaction
-
-
?
myristoyl-CoA + Nef protein
CoA + N-myristoyl-Nef protein
-
HIV-1 accessory protein Nef, usage of C-terminally 6xHis-tagged Nef SF2
-
-
?
myristoyl-CoA + p60src-derived peptide
N-myristoylated p60src-derived peptide + CoA
myristoyl-CoA + peptide CAP5.5
CoA + N-myristoyl-peptide CAP5.5
myristoyl-CoA + peptide Hs pp60src(2-9)
CoA + N-myristoyl-peptideHs pp60src(2-9)
-
-
-
-
?
myristoyl-CoA + peptide pp60src(2-16)
CoA + N-myristoyl-peptideHs pp60src(2-16)
-
sequence GSNKSKPKDASQRRR-NH2
-
-
?
myristoyl-CoA + Pr55gag-precursor-derived octapeptide
N-myristoylated Pr55gag-precursor-derived peptide + CoA
-
peptide substrate is derived from human immunodeficiency virus
-
?
myristoyl-CoA + protein
?
myristoyl-CoA + tumor necrosis factor-derived peptide
N-myristoylated tumor necrosis factor-derived peptide + CoA
-
-
-
?
myristoyl-CoA + vinculin
?
-
-
-
-
?
n-decanoyl-CoA + glycylpeptide
N-decanoylglycylpeptide + CoA
palmitoyl-CoA + Gly-Asn-Ala-Ala-Ala-Ala-Arg-Arg
N-palmitoyl-Gly-Asn-Ala-Ala-Ala-Ala-Arg-Arg + CoA
-
-
-
-
?
palmitoyl-CoA + glycylpeptide
N-palmitoylglycylpeptide + CoA
stearoyl-CoA + glycylpeptide
N-stearoylglycylpeptide + CoA
poor substrate
-
-
?
tetradecanoyl-CoA + GAAPSKIV-NH2
CoA + N-tetradecanoyl-GAAPSKIV-NH2
tetradecanoyl-CoA + GLTISKLFRR
CoA + N-tetradecanoyl-GLTISKLFRR
tetradecanoyl-CoA + GLYASKLA
CoA + N-tetradecanoyl-GLYASKLA
tetradecanoyl-CoA + glycyl-HIV1 Gag protein N-terminal peptide
CoA + N-tetradecanoyl-glycyl-HIV1 Gag protein N-terminal peptide
tetradecanoyl-CoA + glycyl-HIV1 Nef protein N-terminal peptide
CoA + N-tetradecanoyl-glycyl-HIV1 Nef protein N-terminal peptide
tetradecanoyl-CoA + glycyl-pp60cSrc
CoA + N-tetradecanoyl-glycyl-pp60cSrc
i.e. myristoyl-CoA
-
-
?
tetradecanoyl-CoA + glycyl-pp60c Src
CoA + N-tetradecanoyl-glycyl-pp60c Src
i.e. myristoyl-CoA
-
-
?
tetradecanoyl-CoA + glycyl-pp60c-Src
CoA + N-tetradecanoyl-glycyl-pp60c-Src
tetradecanoyl-CoA + glycylpeptide
CoA + N-tetradecanoyl-glycylpeptide
tetradecanoyl-CoA + glycylpeptide
CoA + N-tetradecanoylglycylpeptide
tetradecanoyl-CoA + GLYVSRLFNRLFQKK(biotin)
CoA + N-tetradecanoyl-GLYVSRLFNRLFQKK(biotin)
tetradecanoyl-CoA + Plasmodium falciparum ADP ribosylation factor 1 peptide
CoA + N-myristoylated Plasmodium falciparum ADP ribosylation factor 1 peptide
-
model substrate, N-myristoylation of a glycine residue
-
-
ir
additional information
?
-
lauroyl-CoA + glycylpeptide
N-lauroylglycylpeptide + CoA
low activity
-
-
?
lauroyl-CoA + glycylpeptide
N-lauroylglycylpeptide + CoA
-
-
-
-
?
myristoleoyl-CoA + CAP5.5
N-myristoleoyl-CAP5.5 + CoA
acceptor is biotin-tagged cytoskeleton-associated protein 5.5
-
-
?
myristoleoyl-CoA + CAP5.5
N-myristoleoyl-CAP5.5 + CoA
acceptor is biotin-tagged cytoskeleton-associated protein 5.5
-
-
?
myristoyl-CoA + cAMP-dependent protein kinase-derived peptide
N-myristoylated cAMP-dependent protein kinase-derived peptide + CoA
-
-
-
?
myristoyl-CoA + cAMP-dependent protein kinase-derived peptide
N-myristoylated cAMP-dependent protein kinase-derived peptide + CoA
-
-
-
-
?
myristoyl-CoA + cAMP-dependent protein kinase-derived peptide
N-myristoylated cAMP-dependent protein kinase-derived peptide + CoA
-
-
-
?
myristoyl-CoA + cAMP-dependent protein kinase-derived peptide
N-myristoylated cAMP-dependent protein kinase-derived peptide + CoA
-
-
-
?
myristoyl-CoA + cAMP-dependent protein kinase-derived peptide
N-myristoylated cAMP-dependent protein kinase-derived peptide + CoA
-
i.e. Gly-Asn-Ala-Ala-Ala-Ala-Lys-Lys-Arg-Arg
-
-
?
myristoyl-CoA + cAMP-dependent protein kinase-derived peptide
N-myristoylated cAMP-dependent protein kinase-derived peptide + CoA
-
-
-
-
?
myristoyl-CoA + Gly-Asn-Ala-Ala-Ala-Ala-Arg-Arg
N-myristoyl-Gly-Asn-Ala-Ala-Ala-Ala-Arg-Arg + CoA
-
-
-
-
?
myristoyl-CoA + Gly-Asn-Ala-Ala-Ala-Ala-Arg-Arg
N-myristoyl-Gly-Asn-Ala-Ala-Ala-Ala-Arg-Arg + CoA
cAMP-dependent protein kinase-derived peptide
-
-
?
myristoyl-CoA + Gly-Asn-Ala-Ala-Ala-Ala-Arg-Arg
N-myristoyl-Gly-Asn-Ala-Ala-Ala-Ala-Arg-Arg + CoA
-
-
-
-
?
myristoyl-CoA + Gly-Asn-Ala-Ala-Ala-Ala-Arg-Arg
N-myristoyl-Gly-Asn-Ala-Ala-Ala-Ala-Arg-Arg + CoA
-
-
-
?
myristoyl-CoA + Gly-Asn-Ala-Ala-Ala-Ala-Arg-Arg
N-myristoyl-Gly-Asn-Ala-Ala-Ala-Ala-Arg-Arg + CoA
-
-
-
-
?
myristoyl-CoA + Gly-Asn-Ala-Ala-Ala-Ala-Arg-Arg
N-myristoyl-Gly-Asn-Ala-Ala-Ala-Ala-Arg-Arg + CoA
-
-
-
-
?
myristoyl-CoA + Gly-Asn-Ala-Ala-Ala-Ala-Arg-Arg
N-myristoyl-Gly-Asn-Ala-Ala-Ala-Ala-Arg-Arg + CoA
-
-
-
-
?
myristoyl-CoA + Gly-Asn-Ala-Ala-Ser-Ala-Arg-Arg
N-myristoyl-Gly-Asn-Ala-Ala-Ser-Ala-Arg-Arg + CoA
-
-
-
-
?
myristoyl-CoA + Gly-Asn-Ala-Ala-Ser-Ala-Arg-Arg
N-myristoyl-Gly-Asn-Ala-Ala-Ser-Ala-Arg-Arg + CoA
-
-
-
-
?
myristoyl-CoA + Gly-Asn-Ala-Ala-Ser-Ala-Arg-Arg
N-myristoyl-Gly-Asn-Ala-Ala-Ser-Ala-Arg-Arg + CoA
-
-
-
-
?
myristoyl-CoA + Gly-Asn-Ala-Ala-Ser-Tyr-Arg-Arg
N-myristoyl-Gly-Asn-Ala-Ala-Ser-Tyr-Arg-Arg + CoA
-
-
-
?
myristoyl-CoA + Gly-Asn-Ala-Ala-Ser-Tyr-Arg-Arg
N-myristoyl-Gly-Asn-Ala-Ala-Ser-Tyr-Arg-Arg + CoA
-
-
-
-
?
myristoyl-CoA + Gly-Asn-Ala-Ala-Ser-Tyr-Arg-Arg
N-myristoyl-Gly-Asn-Ala-Ala-Ser-Tyr-Arg-Arg + CoA
-
-
-
-
?
myristoyl-CoA + Gly-Ser-Ser-Lys-Ser-Lys-Pro-Lys-Arg
N-myristoyl-Gly-Ser-Ser-Lys-Ser-Lys-Pro-Lys-Arg + CoA
-
pp60src-derived peptide
-
-
?
myristoyl-CoA + Gly-Ser-Ser-Lys-Ser-Lys-Pro-Lys-Arg
N-myristoyl-Gly-Ser-Ser-Lys-Ser-Lys-Pro-Lys-Arg + CoA
-
pp60src-derived peptide
-
?
myristoyl-CoA + Gly-Ser-Ser-Lys-Ser-Lys-Pro-Lys-Arg
N-myristoyl-Gly-Ser-Ser-Lys-Ser-Lys-Pro-Lys-Arg + CoA
-
pp60src-derived peptide
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
substrate specificity
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
altered fatty acid chain length
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
specific for myristoyl-CoA
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
essential for growth
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
-
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
substrate specificity
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
altered fatty acid chain length
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
specific for Gly at N-terminus
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
specific for Gly at N-terminus
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
enzyme is possibly regulated by calpains in vivo
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
-
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
overview peptides and proteins
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
-
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
specific for Gly at N-terminus
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
the enzyme plays a major role in the process of myristoylation of oncoproteins including the c-src family
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
N-myristoylation is a process of covalent irreversible protein modification that promotes association of proteins with membranes
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
cross talk between enzyme and protein substrate
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
the enzyme is essential for viability in Leishmania, constitutively expressed in all parasite stages
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
-
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
substrate specificity
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
overview peptides and proteins
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
specific for Gly at N-terminus
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
diverse protein substrates, protein biosynthesis
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
N-myristoyltransferase 1 is not essential for the viability of mammalian cells but is required for development, likely because it is the principal N-myristoyltransferase in early embryogenesis
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
-
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
substrate specificity
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
substrate specificity
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
substrate specificity
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
cAMP-dependent protein kinase-derived peptide
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
specific for Gly at N-terminus
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
p60src-derived peptides
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
p60src-derived peptides
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
-
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
-
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
-
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
-
-
ir
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
substrate specificity
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
substrate specificity
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
myristoyl-CoA can be replaced by CoA-derivatives of hydroxytetradecanoic acids, azidoaromatic analogues of myristic acid, omega-nitrocarboxylic acids, halogen- and haloaromatic analogues of myristic acid and, with low activity, by dicarboxylic fatty acids
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
stereochemical requirements
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
stereochemical requirements
-
-
ir
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
biotinylated peptides
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
altered fatty acid chain length
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
myristoyl-peptides can compete with myristoyl-CoA for the binding site
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
myristoyl-CoA can be replaced by oxygen or sulfur mono-substituted analogs
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
myristoyl-CoA can be replaced by phenyl-, furyl-, thienyl-, acylohexyl-substituted fatty acids
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
myristoyl-CoA can be replaced by unsaturated fatty acids
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
myristoyl-CoA can be replaced by oxygen or sulfur di-substituted analogs
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
specific for uncharged amino acid at position 2 of peptide chain, no peptides with bulky hydrophobic side chains at position 2, broad spectrum of amino acids in position 3, overview
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
overview peptides and proteins
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
specific for Gly at N-terminus
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
specific for Gly at N-terminus
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
specific for Gly at N-terminus
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
specific for Gly at N-terminus
-
-
ir
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
specific for Gly at N-terminus
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
specific for myristoyl-CoA
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
specific for myristoyl-CoA
-
-
ir
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
p60src-derived peptides
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
p60src-derived peptides
-
-
ir
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
enzyme is essential for vegetative growth
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
enzyme is essential for vegetative growth
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
substrate specificity
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
altered fatty acid chain length
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
myristoyl-CoA can be replaced by oxygen or sulfur mono-substituted analogs
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
myristoyl-CoA can be replaced by unsaturated fatty acids
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
substrate specificity
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
altered fatty acid chain length
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
the enzyme is essential for both life cycle stages of Trypanosoma brucei
-
-
?
myristoyl-CoA + M2 gene segment of reovirus type 3-derived peptide
N-myristoylated M2 gene segment of reovirus type 3-derived peptide + CoA
-
-
-
-
?
myristoyl-CoA + M2 gene segment of reovirus type 3-derived peptide
N-myristoylated M2 gene segment of reovirus type 3-derived peptide + CoA
-
i.e. Gly-Asn-Ala-Ser-Ser-Ile-Lys-Lys-Lys
-
-
?
myristoyl-CoA + p60src-derived peptide
N-myristoylated p60src-derived peptide + CoA
-
-
-
?
myristoyl-CoA + p60src-derived peptide
N-myristoylated p60src-derived peptide + CoA
-
-
-
?
myristoyl-CoA + p60src-derived peptide
N-myristoylated p60src-derived peptide + CoA
-
-
-
-
?
myristoyl-CoA + p60src-derived peptide
N-myristoylated p60src-derived peptide + CoA
-
retina enzyme
-
?
myristoyl-CoA + p60src-derived peptide
N-myristoylated p60src-derived peptide + CoA
-
-
-
-
?
myristoyl-CoA + p60src-derived peptide
N-myristoylated p60src-derived peptide + CoA
-
hexadecapeptide from N-terminus
-
?
myristoyl-CoA + p60src-derived peptide
N-myristoylated p60src-derived peptide + CoA
decapeptide, best substrate
-
-
?
myristoyl-CoA + p60src-derived peptide
N-myristoylated p60src-derived peptide + CoA
-
-
-
-
?
myristoyl-CoA + p60src-derived peptide
N-myristoylated p60src-derived peptide + CoA
-
-
-
?
myristoyl-CoA + peptide CAP5.5
CoA + N-myristoyl-peptide CAP5.5
-
N-myristoylation of the synthetic peptide CAP5.5, derived from the N-terminus of the Trypanosoma brucei CAP5.5 protein
-
-
?
myristoyl-CoA + peptide CAP5.5
CoA + N-myristoyl-peptide CAP5.5
N-myristoylation of the synthetic peptide CAP5.5, derived from the N-terminus of the Trypanosoma brucei CAP5.5 protein
-
-
?
myristoyl-CoA + peptide CAP5.5
CoA + N-myristoyl-peptide CAP5.5
-
N-myristoylation of the synthetic peptide CAP5.5, derived from the N-terminus of the Trypanosoma brucei CAP5.5 protein
-
-
?
myristoyl-CoA + protein
?
-
-
-
?
myristoyl-CoA + protein
?
-
proteins involved in metabolic regulation, e.g. catalytic subunit of protein kinase A and G protein alpha subunit
-
-
?
myristoyl-CoA + protein
?
-
natural protein substrates are: catalytic subunit of cAMP-dependent protein kinase, p60src, phosphatases, e.g. calcineurin B, transmembrane signalling proteins, e.g. alpha-subunits of heterotrimeric G proteins, gag polyprotein precursors of several retroviruses, capsid proteins of some parvoviruses and picornaviruses
-
-
ir
myristoyl-CoA + protein
?
-
overview proteins
-
-
?
n-decanoyl-CoA + glycylpeptide
N-decanoylglycylpeptide + CoA
low activity
-
-
?
n-decanoyl-CoA + glycylpeptide
N-decanoylglycylpeptide + CoA
-
-
-
-
?
palmitoyl-CoA + glycylpeptide
N-palmitoylglycylpeptide + CoA
poor substrate
-
-
?
palmitoyl-CoA + glycylpeptide
N-palmitoylglycylpeptide + CoA
-
poor substrate
-
-
?
palmitoyl-CoA + glycylpeptide
N-palmitoylglycylpeptide + CoA
-
no activity
-
-
?
palmitoyl-CoA + glycylpeptide
N-palmitoylglycylpeptide + CoA
-
no activity
-
-
?
palmitoyl-CoA + glycylpeptide
N-palmitoylglycylpeptide + CoA
-
-
-
-
?
palmitoyl-CoA + glycylpeptide
N-palmitoylglycylpeptide + CoA
-
poor substrate
-
-
?
tetradecanoyl-CoA + GAAPSKIV-NH2
CoA + N-tetradecanoyl-GAAPSKIV-NH2
NMT catalyses the attachment of the 14C saturated fatty acid, myristate, to the N-terminal glycine residue of a protein. The fatty acyl-CoA is largely buried in the N-terminal lobe, its binding leading to the loosening of a flap, which in unliganded NMT structures, occludes the protein substrate binding site in the C-terminal lobe, substrate binding structure, overview
-
-
?
tetradecanoyl-CoA + GAAPSKIV-NH2
CoA + N-tetradecanoyl-GAAPSKIV-NH2
NMT catalyses the attachment of the 14C saturated fatty acid, myristate, to the N-terminal glycine residue of a protein. The fatty acyl-CoA is largely buried in the N-terminal lobe, its binding leading to the loosening of a flap, which in unliganded NMT structures, occludes the protein substrate binding site in the C-terminal lobe, substrate binding structure, overview
-
-
?
tetradecanoyl-CoA + GLTISKLFRR
CoA + N-tetradecanoyl-GLTISKLFRR
NMT catalyses the attachment of the 14C saturated fatty acid, myristate, to the N-terminal glycine residue of a protein. The fatty acyl-CoA is largely buried in the N-terminal lobe, its binding leading to the loosening of a flap, which in unliganded NMT structures, occludes the protein substrate binding site in the C-terminal lobe, substrate binding structure, overview
-
-
?
tetradecanoyl-CoA + GLTISKLFRR
CoA + N-tetradecanoyl-GLTISKLFRR
NMT catalyses the attachment of the 14C saturated fatty acid, myristate, to the N-terminal glycine residue of a protein. The fatty acyl-CoA is largely buried in the N-terminal lobe, its binding leading to the loosening of a flap, which in unliganded NMT structures, occludes the protein substrate binding site in the C-terminal lobe, substrate binding structure, overview
-
-
?
tetradecanoyl-CoA + GLYASKLA
CoA + N-tetradecanoyl-GLYASKLA
-
i.e. myristoyl-CoA
-
-
?
tetradecanoyl-CoA + GLYASKLA
CoA + N-tetradecanoyl-GLYASKLA
-
i.e. myristoyl-CoA
-
-
?
tetradecanoyl-CoA + GLYASKLA
CoA + N-tetradecanoyl-GLYASKLA
-
i.e. myristoyl-CoA
-
-
?
tetradecanoyl-CoA + GLYASKLA
CoA + N-tetradecanoyl-GLYASKLA
-
i.e. myristoyl-CoA
-
-
?
tetradecanoyl-CoA + GLYASKLA
CoA + N-tetradecanoyl-GLYASKLA
-
i.e. myristoyl-CoA
-
-
?
tetradecanoyl-CoA + GLYASKLA
CoA + N-tetradecanoyl-GLYASKLA
-
i.e. myristoyl-CoA
-
-
?
tetradecanoyl-CoA + GLYASKLA
CoA + N-tetradecanoyl-GLYASKLA
-
i.e. myristoyl-CoA
-
-
?
tetradecanoyl-CoA + glycyl-HIV1 Gag protein N-terminal peptide
CoA + N-tetradecanoyl-glycyl-HIV1 Gag protein N-terminal peptide
-
-
-
?
tetradecanoyl-CoA + glycyl-HIV1 Gag protein N-terminal peptide
CoA + N-tetradecanoyl-glycyl-HIV1 Gag protein N-terminal peptide
i.e. myristoyl-CoA
-
-
?
tetradecanoyl-CoA + glycyl-HIV1 Nef protein N-terminal peptide
CoA + N-tetradecanoyl-glycyl-HIV1 Nef protein N-terminal peptide
-
-
-
?
tetradecanoyl-CoA + glycyl-HIV1 Nef protein N-terminal peptide
CoA + N-tetradecanoyl-glycyl-HIV1 Nef protein N-terminal peptide
i.e. myristoyl-CoA, NMT2 has approximately 5fold higher catalytic efficiency for the myristoylation of Nef than NMT1
-
-
?
tetradecanoyl-CoA + glycyl-pp60c-Src
CoA + N-tetradecanoyl-glycyl-pp60c-Src
-
-
-
-
?
tetradecanoyl-CoA + glycyl-pp60c-Src
CoA + N-tetradecanoyl-glycyl-pp60c-Src
-
i.e. myristoyl-CoA
-
-
?
tetradecanoyl-CoA + glycylpeptide
CoA + N-tetradecanoyl-glycylpeptide
-
i.e. myristoyl-CoA, the enzyme attaches the fatty acid to a glycine at the N-terminus of proteins
-
-
?
tetradecanoyl-CoA + glycylpeptide
CoA + N-tetradecanoyl-glycylpeptide
i.e. myristoyl-CoA, the enzyme attaches the fatty acid to a glycine at the N-terminus of a number of eukaryotic cellular and viral proteins
-
-
?
tetradecanoyl-CoA + glycylpeptide
CoA + N-tetradecanoyl-glycylpeptide
i.e. myristoyl-CoA, the enzyme attaches the fatty acid to a glycine at the N-terminus of a number of eukaryotic cellular and viral proteins
-
-
?
tetradecanoyl-CoA + glycylpeptide
CoA + N-tetradecanoyl-glycylpeptide
-
-
-
-
?
tetradecanoyl-CoA + glycylpeptide
CoA + N-tetradecanoyl-glycylpeptide
-
i.e. myristoyl-CoA, the enzyme attaches the fatty acid to a glycine at the N-terminus of a number of eukaryotic cellular and viral proteins
-
-
?
tetradecanoyl-CoA + glycylpeptide
CoA + N-tetradecanoylglycylpeptide
-
-
-
-
?
tetradecanoyl-CoA + glycylpeptide
CoA + N-tetradecanoylglycylpeptide
-
covalent attachment of the myristoyl group, generally to the N-terminal glycine residue of proteins. N-myristoylation occurs absolutely on an exposed N-terminal glycine and on a general consesus motif of GXXXS/T, where X is any amino acid
-
-
?
tetradecanoyl-CoA + glycylpeptide
CoA + N-tetradecanoylglycylpeptide
-
posttranslational transfer of a C14 saturated fatty acid (myristic acid) from myristoyl-CoA to the N-terminal glycine residue of target proteins
-
-
?
tetradecanoyl-CoA + glycylpeptide
CoA + N-tetradecanoylglycylpeptide
-
transfer of a C14 saturated fatty acid (myristic acid) from myristoyl-CoA to the N-terminal glycine residue of target proteins
-
-
?
tetradecanoyl-CoA + glycylpeptide
CoA + N-tetradecanoylglycylpeptide
NMT catalyses the attachment of the 14C saturated fatty acid, myristate, to the N-terminal glycine residue of a subset of eukaryotic proteins that function in multiple cellular processes, including vesicular protein trafficking and signal transduction
-
-
?
tetradecanoyl-CoA + glycylpeptide
CoA + N-tetradecanoylglycylpeptide
NMT catalyses the attachment of the 14C saturated fatty acid, myristate, to the N-terminal glycine residue of a subset of eukaryotic proteins that function in multiple cellular processes, including vesicular protein trafficking and signal transduction
-
-
?
tetradecanoyl-CoA + glycylpeptide
CoA + N-tetradecanoylglycylpeptide
-
-
-
-
?
tetradecanoyl-CoA + glycylpeptide
CoA + N-tetradecanoylglycylpeptide
-
covalent attachment of the myristoyl group, generally to the N-terminal glycine residue of proteins. N-myristoylation occurs absolutely on an exposed N-terminal glycine and on a general consesus motif of GXXXS/T, where X is any amino acid
-
-
?
tetradecanoyl-CoA + glycylpeptide
CoA + N-tetradecanoylglycylpeptide
-
-
-
-
?
tetradecanoyl-CoA + glycylpeptide
CoA + N-tetradecanoylglycylpeptide
-
covalent attachment of the myristoyl group, generally to the N-terminal glycine residue of proteins. N-myristoylation occurs absolutely on an exposed N-terminal glycine and on a general consesus motif of GXXXS/T, where X is any amino acid
-
-
?
tetradecanoyl-CoA + GLYVSRLFNRLFQKK(biotin)
CoA + N-tetradecanoyl-GLYVSRLFNRLFQKK(biotin)
NMT catalyses the attachment of the 14C saturated fatty acid, myristate, to the N-terminal glycine residue of a protein. The fatty acyl-CoA is largely buried in the N-terminal lobe, its binding leading to the loosening of a flap, which in unliganded NMT structures, occludes the protein substrate binding site in the C-terminal lobe, substrate binding structure, overview
-
-
?
tetradecanoyl-CoA + GLYVSRLFNRLFQKK(biotin)
CoA + N-tetradecanoyl-GLYVSRLFNRLFQKK(biotin)
NMT catalyses the attachment of the 14C saturated fatty acid, myristate, to the N-terminal glycine residue of a protein. The fatty acyl-CoA is largely buried in the N-terminal lobe, its binding leading to the loosening of a flap, which in unliganded NMT structures, occludes the protein substrate binding site in the C-terminal lobe, substrate binding structure, overview
-
-
?
additional information
?
-
ablating NMT1 is more effective in inhibiting tumor growth than is ablation of NMT2
-
-
?
additional information
?
-
ablating NMT1 is more effective in inhibiting tumor growth than is ablation of NMT2
-
-
?
additional information
?
-
-
ablating NMT1 is more effective in inhibiting tumor growth than is ablation of NMT2
-
-
?
additional information
?
-
NMT1 is critical for tumor cell proliferation. Ablating NMT1 is more effective in inhibiting tumor growth than is ablation of NMT2
-
-
?
additional information
?
-
NMT1 is critical for tumor cell proliferation. Ablating NMT1 is more effective in inhibiting tumor growth than is ablation of NMT2
-
-
?
additional information
?
-
-
NMT1 is critical for tumor cell proliferation. Ablating NMT1 is more effective in inhibiting tumor growth than is ablation of NMT2
-
-
?
additional information
?
-
-
isozyme NMT1 catalyzes myristoylation of various proteins crucial in signal transduction, cellular transformation, and oncogenesis
-
-
?
additional information
?
-
-
strong interaction of NMT2 with caspase-3 with a probable major role in the cellular regulation of NMT2, caspase-3 interaction with NMT2 is stronger than with NMT1. The cellular regulation of NMT1 and NMT2 is mediated by two different signaling molecules, m-calpain and caspase, respectively, overview. Protein-protein interaction of NMT forms and p53
-
-
?
additional information
?
-
N-myristoyltransferase isozymes exhibit differential specificity for human immunodeficiency virus type 1 Gag and Nef, overview
-
-
?
additional information
?
-
N-myristoyltransferase isozymes exhibit differential specificity for human immunodeficiency virus type 1 Gag and Nef, overview
-
-
?
additional information
?
-
-
N-myristoyltransferase isozymes exhibit differential specificity for human immunodeficiency virus type 1 Gag and Nef, overview
-
-
?
additional information
?
-
-
development of a robust sensitive fluorescence-based assay method to study the enzymatic activity of NMT1 and NMT2 based on detection of CoA by 7-diethylamino-3-(4-maleimido-phenyl)-4-methylcoumarin, overview
-
-
?
additional information
?
-
N-myristoylation of the synthetic peptide CAP5.5, derived from the N-terminus of the Trypanosoma brucei CAP5.5 protein, with myristoyl-CoA
-
-
?
additional information
?
-
N-myristoylation of the synthetic peptide CAP5.5, derived from the N-terminus of the Trypanosoma brucei CAP5.5 protein, with myristoyl-CoA
-
-
?
additional information
?
-
-
N-myristoylation of the synthetic peptide CAP5.5, derived from the N-terminus of the Trypanosoma brucei CAP5.5 protein, with myristoyl-CoA
-
-
?
additional information
?
-
NMT acts both as N-terminal lysine and glycine myristoyltransferase
-
-
-
additional information
?
-
-
NMT acts both as N-terminal lysine and glycine myristoyltransferase
-
-
-
additional information
?
-
N-myristoylation of the synthetic peptide CAP5.5, derived from the N-terminus of the Trypanosoma brucei CAP5.5 protein, with myristoyl-CoA
-
-
?
additional information
?
-
-
N-myristoylation of the synthetic peptide CAP5.5, derived from the N-terminus of the Trypanosoma brucei CAP5.5 protein, with myristoyl-CoA
-
-
?
additional information
?
-
the fatty acyl-CoA is largely buried in the N-terminal lobe, its binding leading to the loosening of a flap, which in unliganded NMT structures, occludes the protein substrate binding site in the carboxy-terminal lobe, substrate binding structure, overview
-
-
?
additional information
?
-
-
the fatty acyl-CoA is largely buried in the N-terminal lobe, its binding leading to the loosening of a flap, which in unliganded NMT structures, occludes the protein substrate binding site in the carboxy-terminal lobe, substrate binding structure, overview
-
-
?
additional information
?
-
the fatty acyl-CoA is largely buried in the N-terminal lobe, its binding leading to the loosening of a flap, which in unliganded NMT structures, occludes the protein substrate binding site in the carboxy-terminal lobe, substrate binding structure, overview
-
-
?
additional information
?
-
active site structure, overview
-
-
?
additional information
?
-
-
active site structure, overview
-
-
?
additional information
?
-
isozyme NMT1 catalyzes myristoylation of various proteins crucial in signal transduction, cellular transformation, and oncogenesis
-
-
?
additional information
?
-
isozyme NMT1 catalyzes myristoylation of various proteins crucial in signal transduction, cellular transformation, and oncogenesis
-
-
?
additional information
?
-
-
isozyme NMT1 catalyzes myristoylation of various proteins crucial in signal transduction, cellular transformation, and oncogenesis
-
-
?
additional information
?
-
isozyme NMT2 catalyzes myristoylation of various proteins crucial in signal transduction, cellular transformation, and oncogenesis
-
-
?
additional information
?
-
isozyme NMT2 catalyzes myristoylation of various proteins crucial in signal transduction, cellular transformation, and oncogenesis
-
-
?
additional information
?
-
-
isozyme NMT2 catalyzes myristoylation of various proteins crucial in signal transduction, cellular transformation, and oncogenesis
-
-
?
additional information
?
-
active site structure, overview
-
-
?
additional information
?
-
-
active site structure, overview
-
-
?
additional information
?
-
-
the enzyme catalyzes the cotranslational irreversible addition of a fatty acyl moiety to the N-terminus of proteins
-
-
?
additional information
?
-
-
active site structure, overview
-
-
?
additional information
?
-
-
presence of approximately 60 putative N-myristoylated proteins encoded by the Trypanosoma brucei genome
-
-
?
additional information
?
-
N-myristoylation of the synthetic peptide CAP5.5, derived from the N-terminus of the Trypanosoma brucei CAP5.5 protein, with myristoyl-CoA
-
-
?
additional information
?
-
-
N-myristoylation of the synthetic peptide CAP5.5, derived from the N-terminus of the Trypanosoma brucei CAP5.5 protein, with myristoyl-CoA
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(1R,3S)-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
(1R,3S)-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclopentanecarboxamide
IC50: 0.000015 mM
(1R,3S)-N-{2-[(cyclopeanthylcarbonyl)amino]-benzothiazol-6-yl}-3-[(2-naphthylmethyl) amino] cyclohexanecarboxamide
competitive with the substrate peptide and non-competitive with myristoyl-CoA. IC50: 0.49 nM
(1S,3R)-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
IC50: above 0.00001 mM
(1S,3R)-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclopentanecarboxamide
IC50: 0.000011mM
(2S)-N-(2-cyclohexylethyl)-2-[[N-([3-[4-(2-methyl-1H-imidazol-1-yl)butyl]phenyl]acetyl)-L-seryl]amino]heptanamide
(3R)-3-amino-4-(4-chlorophenyl)-1-[(3R,4S)-3-(hydroxymethyl)-4-(4-methoxyphenyl)pyrrolidin-1-yl]butan-1-one
(3R)-3-amino-4-(4-chlorophenyl)-1-[(3S,4R)-3-(4-chlorophenyl)-4-(hydroxymethyl)pyrrolidin-1-yl]butan-1-one
(4S,5aS,12aS)-2-carbamoyl-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-6-methylidene-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracen-5-yl acetate
1,10-phenanthroline
-
0.1 mM, 30% inhibition
1,12-dodecanedicarboxylic acid
IC50 above 100 mM
1,3-dimyristoylglycerol
IC50 above 100 mM
1-(4-(3,5-dichloro-4-((2-methylpyridin-3-yl)methoxy)phenyl)pyridin-2-yl)piperazine
-
3fold selectivity over human isoform NMT1
1-(4-(3,5-dichloro-4-((2-phenylpyridin-3-yl)methoxy)phenyl)-pyridin-2-yl)piperazine
-
3fold selectivity over human isoform NMT1
1-(4-(3,5-dichloro-4-(pyridin-2-ylmethoxy)phenyl)pyridin-2-yl)-piperazine
-
2fold selectivity over human isoform NMT1; 65fold selectivity over human isoform NMT1
1-(5-chloro-2-[[2-(dimethylamino)ethyl]amino]pyrimidin-4-yl)-N-(2,4-difluorobenzyl)azetidine-3-carboxamide
1-(5-chloro-2-[[2-(dimethylamino)ethyl]amino]pyrimidin-4-yl)-N-[(5-methylpyrazin-2-yl)methyl]azetidine-3-carboxamide
1-(5-[3,4-difluoro-2-[2-(1,3,5-trimethyl-1H-pyrazol-4-yl)ethoxy]phenyl]-1-methyl-1H-indazol-3-yl)-N,N-dimethylmethanamine
-
1-acetyl-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)-2,3-dihydro-1H-indole-5-sulfonamide
-
-
1-Bromo-2-fluorotetradecane
-
-
1-hydroxy-2-[(1-methylethyl)amino]ethyl 2,6-dihydroxybenzoate
1-myristoyl-rac-glycerol
IC50 in the range 1-100 mM
1-O-Acetyl-2-fluorotetradecane
-
-
1-Tetradecanal
IC50 in the range 1-100 mM
1-Tetradecanol
IC50 above 100 mM
1-[(diethylamino)methyl]naphthalen-2-ol
-
-
2,6-dichloro-4-(1,2,3,4-tetrahydroisoquinolin-5-yl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
-
-
2,6-dichloro-4-(2-piperazin-1-ylpyridin-4-yl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)-benzenesulfonamide
-
-
2,6-dichloro-4-(isoquinolin-5-yl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
-
-
2,6-dichloro-4-[2-(4-methylpiperazin-1-yl)pyridin-4-yl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
IC50 value against amastigotes 0.00015 microM
2,6-dichloro-4-[2-(4-methylpiperazin-1-yl)pyridin-4-yl]-N-(1,5-dimethyl-3-isobutyl-1H-pyrazol-4-yl)benzenesulfonamide
inhibits the enzyme and is fungicidal under partially repressive nmt conditions
2,6-dichloro-4-[2-(piperazin-1-yl)pyridin-4-yl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
2,6-dichloro-4-[6-(piperazin-1-yl)pyridin-3-yl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
-
-
2,6-dichloro-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
-
-
2-(3,4-dihydroxyphenyl)ethyl 6-deoxy-alpha-L-gulopyranosyl-(1->3)-[alpha-L-ribopyranosyl-(1->6)]-4-O-[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]-beta-L-glucopyranoside
inhibitor identified by screening of chemical libraries using different docking programs, substance is predicted not to inhibit human isoforms
2-(3,4-dihydroxyphenyl)ethyl alpha-L-gulopyranosyl-(1->2)-6-deoxy-alpha-L-gulopyranosyl-(1->3)-4-O-[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]-beta-L-glucopyranoside
inhibitor identified by screening of chemical libraries using different docking programs, substance is predicted not to inhibit human isoforms
2-(4-fluorophenyl)-N-[3-(piperidin-4-yl)-1H-indol-5-yl]acetamide
2-(acetylamino)-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
IC50: above 0.01 mM
2-(benzylamino)-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
IC50: above 0.01 mM
2-(diethylamino)ethyl 2-[(cyclohexylcarbonyl)amino]-1,3-benzothiazole-6-carboxylate
2-([2-[(2,3-difluorophenoxy)methyl]-3-methyl-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)ethanamine
-
2-([2-[(2,4-difluorophenoxy)methyl]-3-methyl-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)ethanamine
-
2-([2-[(2-fluorophenoxy)methyl]-3-methyl-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)ethanamine
-
2-([2-[(3-fluorophenoxy)methyl]-3-methyl-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)ethanamine
-
2-([2-[(4-chlorophenoxy)methyl]-3-methyl-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)ethanamine
-
2-([2-[(4-fluorophenoxy)methyl]-3-methyl-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)ethanamine
-
2-([3-methyl-2-[(2,3,4-trifluorophenoxy)methyl]-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)ethanamine
-
2-([3-methyl-2-[(phenylsulfanyl)methyl]-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)ethanamine
-
2-([[(1R,3S)-3-[[(5-chloro-7-methylnaphthalen-2-yl)methyl]amino]cyclohexyl]acetyl]amino)-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
2-([[4-(aminomethyl)cyclohexyl]carbonyl]amino)-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
2-([[trans-4-(aminomethyl)cyclohexyl]carbonyl]amino)-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
2-amino-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
IC50: above 0.01 mM
2-dodecylglycidoyl-S-CoA
IC50 below 1 mM
2-Fluoromyristic acid
-
-
2-fluoromyristoyl-CoA
-
-
2-Fluorotetradecan-1-ol
-
-
2-Hydroxymyristic acid
-
-
2-hydroxymyristoyl-CoA
-
-
2-oxo-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide
-
-
2-[(2-methylpropanoyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
2-[(3-methyl-4-[2-[(pyridin-3-ylmethyl)amino]ethoxy]-1-benzofuran-2-yl)methoxy]benzonitrile
-
2-[(4-methoxybenzyl)amino]-5,5-dimethyl-4,7-dihydro-5H-thieno[2,3-c]pyran-3-carbonitrile
-
-
2-[(cyclobutylcarbonyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
2-[(cyclohexanecarbonyl)amino]-N-[(2-naphthylmethyl)amino]ethyl-benzothiazole-6-carboxamide
2-[(cyclohexylcarbonyl)amino]-1-methyl-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1H-benzimidazole-5-carboxamide
IC50: above 0.1 mM
2-[(cyclohexylcarbonyl)amino]-1-methyl-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1H-benzimidazole-6-carboxamide
IC50: above 0.1 mM
2-[(cyclohexylcarbonyl)amino]-N-(3-[[(naphthalen-2-ylmethyl)amino]methyl]benzyl)-1,3-benzothiazole-6-carboxamide
IC50: 0.0019 mM
2-[(cyclohexylcarbonyl)amino]-N-(4-[[(naphthalen-2-ylmethyl)amino]methyl]benzyl)-1,3-benzothiazole-6-carboxamide
IC50: above 0.1 mM
2-[(cyclohexylcarbonyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-5-carboxamide
IC50: 0.0068 mM
2-[(cyclohexylcarbonyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-7-carboxamide
IC50: 0.001 mM
2-[(cyclohexylcarbonyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzoxazole-5-carboxamide
IC50: 0.0011 mM
2-[(cyclohexylcarbonyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzoxazole-6-carboxamide
IC50: 0.00029 mM
2-[(cyclohexylcarbonyl)amino]-N-[3-[(naphthalen-2-ylmethyl)amino]propyl]-1,3-benzothiazole-6-carboxamide
2-[(cyclohexylcarbonyl)amino]-N-[4-[(naphthalen-2-ylmethyl)amino]butyl]-1,3-benzothiazole-6-carboxamide
2-[(cyclohexylcarbonyl)amino]-N-[5-[(naphthalen-2-ylmethyl)amino]pentyl]-1,3-benzothiazole-6-carboxamide
2-[(cyclohexylmethyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
IC50: above 0.001 mM
2-[(cyclopentylcarbonyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
2-[(methanesulfonyl)amino]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzamide
2-[([(1R,3S)-3-[(1-benzofuran-5-ylmethyl)amino]cyclohexyl]acetyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
2-[([(1R,3S)-3-[(1-benzofuran-6-ylmethyl)amino]cyclohexyl]acetyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
2-[([(1R,3S)-3-[(1-benzofuran-6-ylmethyl)amino]cyclohexyl]carbonyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
2-[([(1R,3S)-3-[(1H-indol-5-ylmethyl)amino]cyclohexyl]acetyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
2-[([(1R,3S)-3-[(1H-indol-6-ylmethyl)amino]cyclohexyl]acetyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
2-[[(2,5-dimethoxyphenyl)carbonyl]amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
2-[[(2-chloropyridin-3-yl)carbonyl]amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
2-[[(3,4-dichlorophenyl)carbonyl]amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
2-[[(4-chlorophenyl)carbonyl]amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
2-[[3-methyl-2-(2-phenylethyl)-1-benzofuran-4-yl]oxy]-N-(pyridin-3-ylmethyl)ethanamine
-
2-[[3-methyl-2-(phenoxymethyl)-1-benzofuran-4-yl]oxy]-N-(pyridin-3-ylmethyl)ethanamine
-
3',5'-dichloro-4'-[(1,3,5-trimethyl-1H-pyrazol-4-yl)sulfamoyl]biphenyl-3-carboxamide
-
-
3,3'-[(3-carboxy-4-oxocyclohexa-2,5-dien-1-ylidene)methanediyl]bis(6-hydroxybenzoic acid)
3,5-dichloro-3'-[(4-methylpiperazin-1-yl)methyl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)biphenyl-4-sulfonamide
-
-
3,5-dichloro-3'-[(diethylamino)methyl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)biphenyl-4-sulfonamide
-
-
3,5-dichloro-4'-[(4-methylpiperazin-1-yl)methyl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)biphenyl-4-sulfonamide
-
-
3,5-dichloro-4'-[(diethylamino)methyl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)biphenyl-4-sulfonamide
-
-
3-(methyl[6-methyl-2-[methyl(1-methylpiperidin-4-yl)amino]thieno[3,2-d]pyrimidin-4-yl]amino)propanenitrile
3-([3-methyl-2-[(2,3,4-trifluorophenoxy)methyl]-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)propan-1-amine
3-([3-methyl-2-[(2,3,4-trifluorophenoxy)methyl]-1-benzofuran-4-yl]oxy)-N-[(pyridin-3-yl)methyl]propan-1-amine
3-butyl-4-(but-3-yn-1-ylsulfanyl)-6-methoxy-2-methylquinoline
-
-
3-butyl-6-methoxy-2-methyl-4-[(2-phenylethyl)sulfanyl]quinoline
-
-
3-cyano-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
-
-
3-tetradecyn-1-ol
IC50 above 100 mM
3-[(2-bromo-3-butyl-6-methoxyquinolin-4-yl)sulfanyl]propanenitrile
-
-
3-[(3-butyl-6-methoxy-2-methylquinolin-4-yl)sulfanyl]propan-1-ol
-
-
3-[(3-butyl-6-methoxy-2-methylquinolin-4-yl)sulfanyl]propanenitrile
-
-
3-[(3-butyl-6-methoxyquinolin-4-yl)sulfanyl]propanenitrile
-
-
3-[(3-ethyl-6-methoxy-2-methylquinolin-4-yl)sulfanyl]propanenitrile
-
-
3-[(6-methoxy-2-methylquinolin-4-yl)sulfanyl]propanenitrile
-
-
3-[[3-methyl-2-[[2,3,4-tris(fluoranyl)phenoxy]methyl]-1-benzofuran-4-yl]oxy]-N-(pyridin-3-ylmethyl)propan-1-amine
i.e. Ro-09-4879
4-(1H-pyrazol-1-yl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
-
-
4-(4,5-dihydroxy-9-methyl-3-oxo-1,3,3a,4,9,9a-hexahydronaphtho[2,3-c]furan-1-yl)-2,5,6-trihydroxycyclohexa-2,4-diene-1-carboxamide
4-(4,5-dihydroxy-9-methyl-3-oxo-1,3,3a,4,9,9a-hexahydronaphtho[2,3-c]furan-1-yl)-2,5-dihydroxybenzamide
4-(4-chloro-2-[5-[(trimethyl-1H-pyrazol-4-yl)methyl]-1,3,4-oxadiazol-2-yl]phenoxy)piperidine
high affinity inhibitor of Leishmania donovani, does not not display significant selectivity for Leishmania donovania over the human enzyme. Compound does not display any macrophage toxicity up to 0.09 mM
4-bromo-2,6-dichloro-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)-benzenesulfonamide
-
-
4-bromo-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzamide
-
-
4-bromo-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
-
-
4-bromo-N-(2-methylpropyl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzamide
-
-
4-bromo-N-methyl-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
-
-
4-bromo-N-[(1,3,5-trimethyl-1H-pyrazol-4-yl)methyl]benzenesulfonamide
-
-
4-cyano-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
-
-
4-methoxy-2,3,6-trimethyl-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
-
-
4-methoxy-2,3,6-trimethyl-N-(1H-pyrazol-3-yl)benzenesulfonamide
-
-
4-methoxy-2,3,6-trimethyl-N-(2-methylpyridin-3-yl)benzenesulfonamide
-
-
4-methoxy-2,3,6-trimethyl-N-(pyridin-3-yl)benzenesulfonamide
-
-
4-methoxy-2,3,6-trimethyl-N-phenylbenzenesulfonamide
-
-
4-methoxy-2,3,6-trimethyl-N-[(1,3,5-trimethyl-1H-pyrazol-4-yl)methyl]benzenesulfonamide
-
-
4-methyl-N-[2-[(7-methylthieno[3,2-d]pyrimidin-4-yl)sulfanyl]phenyl]benzene-1-sulfonamide
4-[(2-[5-[(1,3,5-trimethyl-1H-pyrazol-4-yl)methyl]-1,3,4-oxadiazol-2-yl]-1-benzothiophen-3-yl)oxy]piperidine
4-[(3-butyl-6-methoxy-2-methylquinolin-4-yl)sulfanyl]butanenitrile
-
-
4-[(3-methyl-4-[2-[(pyridin-3-ylmethyl)amino]ethoxy]-1-benzofuran-2-yl)methoxy]benzonitrile
-
4-[(4-bromophenoxy)methyl]-1,3,5-trimethyl-1H-pyrazole
-
-
4-[[(4-bromophenyl)sulfonyl]methyl]-1,3,5-trimethyl-1H-pyrazole
-
-
5-chloro-2-[[4-(3,5-difluorophenyl)piperidin-1-yl]methyl]-1-methyl-1H-benzimidazole
5-chloro-N-[4-(4-fluorophenoxy)phenyl]-1,3-dimethyl-1H-pyrazole-4-sulfonamide
5-methyl-N-[(5-methyl-3-phenyl-1,2-oxazol-4-yl)methyl]-1-phenyl-1H-pyrazole-4-sulfonamide
6-(2-methyl-1,3-thiazol-4-yl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
-
-
6-(benzylamino)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
-
-
6-(morpholin-4-yl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
-
-
6-([2-[4-(propan-2-yl)piperazin-1-yl]ethyl]amino)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
-
-
6-chloro-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
-
-
6-ethyl-3-(trifluoromethyl)-2,3-dihydro-1,4-benzoxathiine 4,4-dioxide
-
-
6-[(1H-indol-5-ylmethyl)amino]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
-
-
6-[2-(4-methylpiperazin-1-yl)ethylamino]pyridine-3-sulfonic acid (1,3,5-trimethyl-1H-pyrazol-4-yl)amide
-
-
6-[3-(piperazin-1-yl)piperidin-1-yl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
-
-
6-[3-(piperazin-1-yl)pyrrolidin-1-yl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
-
-
6-[[2-(1-methylpiperidin-4-yl)ethyl]amino]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
-
-
6-[[2-(1H-imidazol-1-yl)ethyl]amino]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
-
-
6-[[2-(4-benzylpiperazin-1-yl)ethyl]amino]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
-
-
6-[[2-(4-methylpiperazin-1-yl)ethyl]amino]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
-
-
6-[[2-(4-phenylpiperazin-1-yl)ethyl]amino]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
-
-
6-[[2-(morpholin-4-yl)ethyl]amino]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
-
-
6-[[2-(piperazin-1-yl)ethyl]amino]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
-
-
6-[[2-(piperidin-1-yl)ethyl]amino]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
-
-
6-[[3-(dimethylamino)propyl]amino]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
-
-
6-[[4-[(dimethylamino)methyl]benzyl](methyl)amino]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
-
-
Ala-Leu-Tyr-Ala-Ser-Lys-Leu-Ser
-
competitve against peptide substrate Gly-Leu-Tyr-Ala-Ser-Lys-Leu-Ser
benzyl-{3-[2-(2-ethoxymethyl-benzofuran-5-ylmethoxymethyl)-3-methyl-benzofuran-4-yloxy]-propyl}-amine
-
-
Ca2+
40% inhibition at 5 mM, activation at lower concentrations below 0.25 mM
cis-4-[(naphthalen-2-ylmethyl)amino]-N-(6-pyridin-2-yl-1,3-benzothiazol-2-yl)cyclohexanecarboxamide
cis-N-(6-fluoro-1,3-benzothiazol-2-yl)-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
cis-N-1,3-benzothiazol-2-yl-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
D-Ala-Leu-Ala-Ala-Ala-Ala-Arg-Arg
-
-
D-Ala-Phe-Ala-Ala-Ala-Ala-Arg-Arg
-
-
D-Ala-Tyr-Ala-Ala-Ala-Ala-Arg-Arg
-
-
D-Ala-Val-Ala-Ala-Ala-Ala-Arg-Arg
-
-
ethyl 1-[4-[(4-methoxybenzene-1-sulfonyl)amino]phenyl]-3,5-dimethyl-1H-pyrazole-4-carboxylate
ethyl 3-(1-methylethyl)-4-[2-[(pyridin-3-ylmethyl)amino]ethoxy]-1-benzofuran-2-carboxylate
-
ethyl 3-cyclopropyl-4-[2-[(pyridin-3-ylmethyl)amino]ethoxy]-1-benzofuran-2-carboxylate
-
ethyl 3-ethyl-4-[2-[(pyridin-3-ylmethyl)amino]ethoxy]-1-benzofuran-2-carboxylate
-
ethyl 3-methyl-4-(3-piperidin-1-ylpropoxy)-1-benzofuran-2-carboxylate
-
ethyl 3-methyl-4-[2-[(pyridin-3-ylmethyl)amino]ethoxy]-1-benzofuran-2-carboxylate
-
ethyl 3-methyl-4-[3-[(pyridin-3-ylmethyl)amino]propoxy]-1-benzofuran-2-carboxylate
ethyl 4-(but-3-yn-1-ylsulfanyl)-6-(1-hydroxyethyl)quinoline-3-carboxylate
-
-
ethyl 4-(but-3-yn-1-ylsulfanyl)-6-chloroquinoline-3-carboxylate
-
-
ethyl 4-(but-3-yn-1-ylsulfanyl)-6-fluoroquinoline-3-carboxylate
-
-
ethyl 4-(but-3-yn-1-ylsulfanyl)-6-methylquinoline-3-carboxylate
-
-
ethyl 4-(ethylsulfanyl)-6-([6-[(piperidin-4-yl)amino]pyridin-3-yl]methoxy)quinoline-3-carboxylate
ethyl 4-(ethylsulfanyl)-6-[(6-[[(3R)-pyrrolidin-3-yl]amino]pyridin-3-yl)methoxy]quinoline-3-carboxylate
ethyl 4-(ethylsulfanyl)-6-[[6-(piperazin-1-yl)pyridin-3-yl]methoxy]quinoline-3-carboxylate
ethyl 4-[(2-cyanoethyl)amino]quinoline-3-carboxylate
-
-
ethyl 4-[(2-cyanoethyl)sulfanyl]-2-ethylquinoline-3-carboxylate
-
-
ethyl 4-[(2-cyanoethyl)sulfanyl]-2-methylquinoline-3-carboxylate
-
-
ethyl 4-[(2-cyanoethyl)sulfanyl]-2-propylquinoline-3-carboxylate
-
-
ethyl 4-[(2-cyanoethyl)sulfanyl]-6-methoxyquinoline-3-carboxylate
-
-
ethyl 4-[(2-cyanoethyl)sulfanyl]-6-[[6-(piperazin-1-yl)pyridin-3-yl]methoxy]quinoline-3-carboxylate
ethyl 4-[(2-cyanoethyl)sulfanyl]quinoline-3-carboxylate
-
-
ethyl 4-[2-(benzylamino)ethoxy]-3-methyl-1-benzofuran-2-carboxylate
-
ethyl 4-[2-(tert-butylamino)ethoxy]-3-methyl-1-benzofuran-2-carboxylate
-
ethyl 4-[2-hydroxy-3-(isopropylamino)propoxy]-3-methyl-1-benzofuran-2-carboxylate
-
-
ethyl 4-[2-hydroxy-3-[(2-methylpropyl)amino]propoxy]-3-methyl-1-benzofuran-2-carboxylate
-
ethyl 4-[2-[(pyridin-3-ylmethyl)amino]ethoxy]-1-benzofuran-2-carboxylate
-
ethyl 4-[3-(tert-butylamino)propoxy]-3-methyl-1-benzofuran-2-carboxylate
-
ethyl 4-[3-[(2,2-dimethylpropyl)amino]-2-hydroxypropoxy]-3-methyl-1-benzofuran-2-carboxylate
-
ethyl 4-[4-(tert-butylamino)butoxy]-3-methyl-1-benzofuran-2-carboxylate
-
ethyl 4-[[5-(tert-butylamino)pentyl]oxy]-3-methyl-1-benzofuran-2-carboxylate
-
ethyl 6-(benzyloxy)-4-(ethylsulfanyl)quinoline-3-carboxylate
ethyl 6-([6-[(2-aminoethyl)amino]pyridin-3-yl]methoxy)-4-(ethylsulfanyl)quinoline-3-carboxylate
ethyl 6-([6-[(3-aminopropyl)amino]pyridin-3-yl]methoxy)-4-(ethylsulfanyl)quinoline-3-carboxylate
ethyl 6-acetyl-4-(but-3-yn-1-ylsulfanyl)quinoline-3-carboxylate
-
-
heat shock cognate protein 70
-
histamine
-
noncompetitive
HIV1 Nef protein N-terminal peptide
Nef peptide acts as a competitive inhibitor for the myristoylation of Gag; Nef peptide acts as a competitive inhibitor for the myristoylation of Gag
-
Inhibitor protein from bovine brain
-
located in the membrane fraction, heat-stable, monomeric, 71 kDa
-
L-histidinol
-
noncompetitive, reversible by L-histidine
lauric acid
IC50 below 1 mM
m-calpain
-
enzyme is inactivated by cleavage, protease is specific for PEST regions, i.e. regions rich in proline, glutamic acid, serine and threonine, calpain-inhibitor calpastatin protects
-
Mn2+
50% inhibition at 5 mM
myristelaidic acid
IC50 below 1 mM
myristic acid
IC50 in the range 1-100 mM
myristoleic acid
IC50 below 1 mM
myristoyl-carba(dethia)-CoA
-
-
N(2-S-CoA-tetradecanoyl)glycinamide
IC50 below 1 mM
N,N-dimethyl-1-[5-(2-methylphenyl)-1H-indazol-3-yl]methanamine
N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
-
-
N-(1-propyl-3,5-dimethyl-1H-pyrazol-4-yl)-4-methoxy-2,3,6-trimethylbenzenesulfonamide
-
-
N-(10-aminodecanoyl)-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide
N-(11-aminoundecanoyl)-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide
-
-
N-(3,4-dimethyl-1,2-oxazol-5-yl)-4-methoxy-2,3,6-trimethylbenzenesulfonamide
-
-
N-(3,5-dimethyl-1,2-oxazol-4-yl)-4-methoxy-2,3,6-trimethylbenzenesulfonamide
-
-
N-(3,5-dimethyl-1-propyl-1H-pyrazol-4-yl)-4-methoxy-2,3,6-trimethylbenzenesulfonamide
-
-
N-(3,5-dimethyl-1H-pyrazol-4-yl)-4-methoxy-2,3,6-trimethylbenzenesulfonamide
-
-
N-(4-bromobenzyl)-1,3,5-trimethyl-1H-pyrazol-4-amine
-
-
N-(4-bromophenyl)-1,3,5-trimethyl-1H-pyrazole-4-carboxamide
-
-
N-(4-bromophenyl)-1,3,5-trimethyl-1H-pyrazole-4-sulfonamide
-
-
N-(6-[[N-(biphenyl-4-ylmethyl)-b-alanyl]amino]-1,3-benzothiazol-2-yl)cyclopentanecarboxamide
IC50: 0.00016 mM
N-(6-[[N-(naphthalen-2-ylmethyl)-b-alanyl]amino]-1,3-benzothiazol-2-yl)cyclohexanecarboxamide
N-(6-[[N-(naphthalen-2-ylmethyl)glycyl]amino]-1,3-benzothiazol-2-yl)cyclohexanecarboxamide
N-(imidazo[1,2-a]pyridin-3-yl)-4-methoxy-2,3,6-trimethylbenzenesulfonamide
-
-
N-([4-[5-(2-methyl-1H-imidazol-1-yl)pentyl]phenyl]acetyl)-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide
N-benzyl-4-methoxy-2,3,6-trimethylbenzenesulfonamide
-
-
N-methyl-5-[5-[(2S)-1-(1-methylpiperidin-4-yl)pyrrolidin-2-yl]-1,2,4-oxadiazol-3-yl]pyridin-2-amine
-
inhibitor identified by virtual screening. Compound shows hydrophobic interactions with Phe82, Tyr209, Val370, and Leu391 and hydrogen bonds with Asn159, Tyr318, and Val370. Binding of the compound may stabilize the enzyme
N-Myristoylglycylpeptides
-
-
-
N-myristoyltransferase inhibitor protein 71
-
-
-
N-[(1R)-1-[3-(3-aminopropyl)-4-(2-cyclohexylethoxy)benzyl]-2-hydroxyethyl]-2-[4-[4-(2-methyl-1H-imidazol-1-yl)butyl]phenyl]acetamide
N-[(3-methyl-4-[2-[(pyridin-3-ylmethyl)amino]ethoxy]-1-benzofuran-2-yl)oxy]aniline
-
N-[(3R)-1-(N-methylglycyl)pyrrolidin-3-yl]-2-(trifluoromethyl)benzamide
N-[(pyridin-3-yl)methyl]-3-([2-[(2,3,4-trifluorophenoxy)methyl]-1,3-benzothiazol-7-yl]oxy)propan-1-amine
N-[1,3-dimethyl-5-(morpholin-4-yl)-1H-pyrazol-4-yl]-4-methoxy-2,3,6-trimethylbenzenesulfonamide
-
-
N-[2-chloro-5-[(3S,4R)-1-[4-(4-chlorophenyl)-3-hydroxybutanoyl]-4-(hydroxymethyl)pyrrolidin-3-yl]phenyl]-2-(4-fluorophenyl)acetamide
N-[2-[(2-methylpropanoyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
IC50: 0.0000033 mM
N-[2-[(cyclobutylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
IC50: 0.0000023 mM
N-[2-[(cyclohexylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
IC50: 0.0000081 mM
N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
IC50: 0.0000012 mM
N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[[(4-phenylcyclohexa-1,5-dien-1-yl)methyl]amino]cyclohexanecarboxamide
IC50: 0.00013 mM
N-[2-[(cyclopropylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
IC50: 0.0000024 mM
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
IC50: above 0.01 mM
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-(propanoylamino)-1,3-benzothiazole-6-carboxamide
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-([[4-(trifluoromethyl)phenyl]carbonyl]amino)-1,3-benzothiazole-6-carboxamide
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-[(phenylcarbonyl)amino]-1,3-benzothiazole-6-carboxamide
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-[(pyrazin-2-ylcarbonyl)amino]-1,3-benzothiazole-6-carboxamide
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-[(pyridin-2-ylcarbonyl)amino]-1,3-benzothiazole-6-carboxamide
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-[(pyridin-2-ylmethyl)amino]-1,3-benzothiazole-6-carboxamide
IC50: above 0.01 mM
N-[4-[(1,3,5-trimethyl-1H-pyrazol-4-yl)sulfamoyl]phenyl]acetamide
-
-
N-[5-[(4R)-1-[(3R)-3-amino-4-(4-chlorophenyl)butanoyl]-4-(hydroxymethyl)pyrrolidin-3-yl]-2-chlorophenyl]-2-(4-fluorophenyl)acetamide
N-[6-([3-[(naphthalen-2-ylmethyl)amino]azetidin-1-yl]carbonyl)-1,3-benzothiazol-2-yl]cyclohexanecarboxamide
N-[6-([3-[(naphthalen-2-ylmethyl)amino]piperidin-1-yl]carbonyl)-1,3-benzothiazol-2-yl]cyclohexanecarboxamide
N-[6-([3-[(naphthalen-2-ylmethyl)amino]pyrrolidin-1-yl]carbonyl)-1,3-benzothiazol-2-yl]cyclohexanecarboxamide
N-[6-([4-[(naphthalen-2-ylmethyl)amino]butanoyl]amino)-1,3-benzothiazol-2-yl]cyclopentanecarboxamide
IC50: 0.000015 mM
N-[6-([4-[(naphthalen-2-ylmethyl)amino]piperidin-1-yl]carbonyl)-1,3-benzothiazol-2-yl]cyclohexanecarboxamide
N-[6-[(4-[[(naphthalen-2-ylmethyl)amino]methyl]piperidin-1-yl)carbonyl]-1,3-benzothiazol-2-yl]cyclohexanecarboxamide
N-[[3'-(6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-5(4H)-ylmethyl)biphenyl-3-yl]methyl]-2-(pyridin-3-yl)ethanamine
Octapeptide inhibitors with hydrophobic amino acid in position 2
-
-
-
p-hydroxymercuribenzoate
-
-
palmitic acid
IC50 in the range 1-100 mM
protein NIP71
-
protein from bovine brain
-
S-(2-bromotetradecanoyl)-CoA
IC50 below 1 mM
S-(2-ketopentadecyl)-CoA
IC50: 0.00006 mM
S-(3-Oxohexadecyl)-CoA
-
-
tert-butyl 4-[2-([5-[(1,3,5-trimethyl-1H-pyrazol-4-yl)sulfamoyl]pyridin-2-yl]amino)ethyl]piperazine-1-carboxylate
-
-
tert-butyl [6-([2-[(naphthalen-2-ylmethyl)amino]ethyl]carbamoyl)-1,3-benzothiazol-2-yl]carbamate
IC50: above 0.01 mM
tetradecyl trimethylammonium bromide
IC50 above 100 mM
tetradecyl triphenylphosphonium bromide
IC50 above 100 mM
trans-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
IC50: 0.000034 mM
Zn2+
80% inhibition at 5 mM
[(3-butyl-6-methoxy-2-methylquinolin-4-yl)sulfanyl]acetonitrile
-
-
[4-[3-(benzylamino)propoxy]-3-methyl-1-benzofuran-2-yl](1-methyl-1H-imidazol-2-yl)methanone
{3-[2-(1H-imidazol-2-yl)-3-methyl-benzofuran-4-yloxy]-propyl}-pyridin-3-ylmethyl-amine
-
-
{3-[2-(2,3-difluoro-phenoxymethyl)-3-methyl-benzofuran-4-yloxy]-propyl}-pyridin-3-ylmethyl-amine
-
-
{3-[2-(2-ethoxymethyl-benzofuran-5-yloxymethyl)-3-methyl-benzofuran-4-yloxy]-propyl}-pyridin-3-ylmethyl-amine
-
-
(1R,3S)-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
IC50: 0.00000049 mM
(1R,3S)-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
-
(1R,3S)-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
-
(1R,3S)-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
-
(1R,3S)-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
-
(1R,3S)-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
-
(1R,3S)-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
-
(1R,3S)-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
-
(2S)-N-(2-cyclohexylethyl)-2-[[N-([3-[4-(2-methyl-1H-imidazol-1-yl)butyl]phenyl]acetyl)-L-seryl]amino]heptanamide
-
(2S)-N-(2-cyclohexylethyl)-2-[[N-([3-[4-(2-methyl-1H-imidazol-1-yl)butyl]phenyl]acetyl)-L-seryl]amino]heptanamide
-
(2S)-N-(2-cyclohexylethyl)-2-[[N-([3-[4-(2-methyl-1H-imidazol-1-yl)butyl]phenyl]acetyl)-L-seryl]amino]heptanamide
-
(3R)-3-amino-4-(4-chlorophenyl)-1-[(3R,4S)-3-(hydroxymethyl)-4-(4-methoxyphenyl)pyrrolidin-1-yl]butan-1-one
-
(3R)-3-amino-4-(4-chlorophenyl)-1-[(3R,4S)-3-(hydroxymethyl)-4-(4-methoxyphenyl)pyrrolidin-1-yl]butan-1-one
-
(3R)-3-amino-4-(4-chlorophenyl)-1-[(3R,4S)-3-(hydroxymethyl)-4-(4-methoxyphenyl)pyrrolidin-1-yl]butan-1-one
-
(3R)-3-amino-4-(4-chlorophenyl)-1-[(3R,4S)-3-(hydroxymethyl)-4-(4-methoxyphenyl)pyrrolidin-1-yl]butan-1-one
-
(3R)-3-amino-4-(4-chlorophenyl)-1-[(3S,4R)-3-(4-chlorophenyl)-4-(hydroxymethyl)pyrrolidin-1-yl]butan-1-one
-
(3R)-3-amino-4-(4-chlorophenyl)-1-[(3S,4R)-3-(4-chlorophenyl)-4-(hydroxymethyl)pyrrolidin-1-yl]butan-1-one
-
(3R)-3-amino-4-(4-chlorophenyl)-1-[(3S,4R)-3-(4-chlorophenyl)-4-(hydroxymethyl)pyrrolidin-1-yl]butan-1-one
-
(3R)-3-amino-4-(4-chlorophenyl)-1-[(3S,4R)-3-(4-chlorophenyl)-4-(hydroxymethyl)pyrrolidin-1-yl]butan-1-one
-
(4S,5aS,12aS)-2-carbamoyl-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-6-methylidene-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracen-5-yl acetate
-
-
(4S,5aS,12aS)-2-carbamoyl-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-6-methylidene-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracen-5-yl acetate
-
-
(4S,5aS,12aS)-2-carbamoyl-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-6-methylidene-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracen-5-yl acetate
-
-
(4S,5aS,12aS)-2-carbamoyl-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-6-methylidene-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracen-5-yl acetate
-
-
(4S,5aS,12aS)-2-carbamoyl-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-6-methylidene-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracen-5-yl acetate
-
-
(4S,5aS,12aS)-2-carbamoyl-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-6-methylidene-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracen-5-yl acetate
-
-
(4S,5aS,12aS)-2-carbamoyl-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-6-methylidene-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracen-5-yl acetate
-
-
1-(5-chloro-2-[[2-(dimethylamino)ethyl]amino]pyrimidin-4-yl)-N-(2,4-difluorobenzyl)azetidine-3-carboxamide
-
1-(5-chloro-2-[[2-(dimethylamino)ethyl]amino]pyrimidin-4-yl)-N-(2,4-difluorobenzyl)azetidine-3-carboxamide
-
1-(5-chloro-2-[[2-(dimethylamino)ethyl]amino]pyrimidin-4-yl)-N-(2,4-difluorobenzyl)azetidine-3-carboxamide
-
1-(5-chloro-2-[[2-(dimethylamino)ethyl]amino]pyrimidin-4-yl)-N-(2,4-difluorobenzyl)azetidine-3-carboxamide
-
1-(5-chloro-2-[[2-(dimethylamino)ethyl]amino]pyrimidin-4-yl)-N-[(5-methylpyrazin-2-yl)methyl]azetidine-3-carboxamide
-
1-(5-chloro-2-[[2-(dimethylamino)ethyl]amino]pyrimidin-4-yl)-N-[(5-methylpyrazin-2-yl)methyl]azetidine-3-carboxamide
-
1-(5-chloro-2-[[2-(dimethylamino)ethyl]amino]pyrimidin-4-yl)-N-[(5-methylpyrazin-2-yl)methyl]azetidine-3-carboxamide
-
1-(5-chloro-2-[[2-(dimethylamino)ethyl]amino]pyrimidin-4-yl)-N-[(5-methylpyrazin-2-yl)methyl]azetidine-3-carboxamide
-
1-hydroxy-2-[(1-methylethyl)amino]ethyl 2,6-dihydroxybenzoate
-
-
1-hydroxy-2-[(1-methylethyl)amino]ethyl 2,6-dihydroxybenzoate
-
-
1-hydroxy-2-[(1-methylethyl)amino]ethyl 2,6-dihydroxybenzoate
-
-
1-hydroxy-2-[(1-methylethyl)amino]ethyl 2,6-dihydroxybenzoate
-
-
1-hydroxy-2-[(1-methylethyl)amino]ethyl 2,6-dihydroxybenzoate
-
-
1-hydroxy-2-[(1-methylethyl)amino]ethyl 2,6-dihydroxybenzoate
-
-
1-hydroxy-2-[(1-methylethyl)amino]ethyl 2,6-dihydroxybenzoate
-
-
2,6-dichloro-4-[2-(piperazin-1-yl)pyridin-4-yl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
-
2,6-dichloro-4-[2-(piperazin-1-yl)pyridin-4-yl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
-
-
2,6-dichloro-4-[2-(piperazin-1-yl)pyridin-4-yl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
-
2,6-dichloro-4-[2-(piperazin-1-yl)pyridin-4-yl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
IC50 value against promastigotes 0.0227 microM, against amastigotes 0.0073 microM
2,6-dichloro-4-[2-(piperazin-1-yl)pyridin-4-yl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
-
2,6-dichloro-4-[2-(piperazin-1-yl)pyridin-4-yl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
-
inhibits growth of Trypanosoma cruzi epimastigotes with EC50 of 6.9 microM, but is about 1000fold less potent than in Trypanosma brucei
2-(4-fluorophenyl)-N-[3-(piperidin-4-yl)-1H-indol-5-yl]acetamide
-
2-(4-fluorophenyl)-N-[3-(piperidin-4-yl)-1H-indol-5-yl]acetamide
-
2-(4-fluorophenyl)-N-[3-(piperidin-4-yl)-1H-indol-5-yl]acetamide
-
2-(4-fluorophenyl)-N-[3-(piperidin-4-yl)-1H-indol-5-yl]acetamide
-
2-(diethylamino)ethyl 2-[(cyclohexylcarbonyl)amino]-1,3-benzothiazole-6-carboxylate
-
-
2-(diethylamino)ethyl 2-[(cyclohexylcarbonyl)amino]-1,3-benzothiazole-6-carboxylate
-
-
2-(diethylamino)ethyl 2-[(cyclohexylcarbonyl)amino]-1,3-benzothiazole-6-carboxylate
-
-
2-(diethylamino)ethyl 2-[(cyclohexylcarbonyl)amino]-1,3-benzothiazole-6-carboxylate
-
-
2-(diethylamino)ethyl 2-[(cyclohexylcarbonyl)amino]-1,3-benzothiazole-6-carboxylate
-
-
2-(diethylamino)ethyl 2-[(cyclohexylcarbonyl)amino]-1,3-benzothiazole-6-carboxylate
-
-
2-(diethylamino)ethyl 2-[(cyclohexylcarbonyl)amino]-1,3-benzothiazole-6-carboxylate
-
-
2-([[(1R,3S)-3-[[(5-chloro-7-methylnaphthalen-2-yl)methyl]amino]cyclohexyl]acetyl]amino)-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
2-([[(1R,3S)-3-[[(5-chloro-7-methylnaphthalen-2-yl)methyl]amino]cyclohexyl]acetyl]amino)-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
2-([[(1R,3S)-3-[[(5-chloro-7-methylnaphthalen-2-yl)methyl]amino]cyclohexyl]acetyl]amino)-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
-
2-([[4-(aminomethyl)cyclohexyl]carbonyl]amino)-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
-
2-([[4-(aminomethyl)cyclohexyl]carbonyl]amino)-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
-
2-([[4-(aminomethyl)cyclohexyl]carbonyl]amino)-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
-
2-([[4-(aminomethyl)cyclohexyl]carbonyl]amino)-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
-
2-([[4-(aminomethyl)cyclohexyl]carbonyl]amino)-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
2-([[4-(aminomethyl)cyclohexyl]carbonyl]amino)-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
-
2-([[4-(aminomethyl)cyclohexyl]carbonyl]amino)-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
2-([[4-(aminomethyl)cyclohexyl]carbonyl]amino)-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
-
2-([[4-(aminomethyl)cyclohexyl]carbonyl]amino)-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
-
2-([[trans-4-(aminomethyl)cyclohexyl]carbonyl]amino)-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
2-([[trans-4-(aminomethyl)cyclohexyl]carbonyl]amino)-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
2-([[trans-4-(aminomethyl)cyclohexyl]carbonyl]amino)-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
2-[(2-methylpropanoyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
IC50: 0.000046 mM
2-[(2-methylpropanoyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
14% inhibition at 0.01 mM
2-[(cyclobutylcarbonyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
IC50: 0.000028 mM
2-[(cyclobutylcarbonyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
22% inhibition at 0.01 mM
2-[(cyclohexanecarbonyl)amino]-N-[(2-naphthylmethyl)amino]ethyl-benzothiazole-6-carboxamide
IC50: 0.0000344 mM
2-[(cyclohexanecarbonyl)amino]-N-[(2-naphthylmethyl)amino]ethyl-benzothiazole-6-carboxamide
49% inhibition at 0.01 mM
2-[(cyclohexylcarbonyl)amino]-N-[3-[(naphthalen-2-ylmethyl)amino]propyl]-1,3-benzothiazole-6-carboxamide
IC50: 0.00011 mM
2-[(cyclohexylcarbonyl)amino]-N-[3-[(naphthalen-2-ylmethyl)amino]propyl]-1,3-benzothiazole-6-carboxamide
61% inhibition at 0.01 mM
2-[(cyclohexylcarbonyl)amino]-N-[4-[(naphthalen-2-ylmethyl)amino]butyl]-1,3-benzothiazole-6-carboxamide
IC50: 0.000074 mM
2-[(cyclohexylcarbonyl)amino]-N-[4-[(naphthalen-2-ylmethyl)amino]butyl]-1,3-benzothiazole-6-carboxamide
43% inhibition at 0.01 mM
2-[(cyclohexylcarbonyl)amino]-N-[5-[(naphthalen-2-ylmethyl)amino]pentyl]-1,3-benzothiazole-6-carboxamide
IC50: 0.0003 mM
2-[(cyclohexylcarbonyl)amino]-N-[5-[(naphthalen-2-ylmethyl)amino]pentyl]-1,3-benzothiazole-6-carboxamide
46% inhibition at 0.01 mM
2-[(cyclopentylcarbonyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
IC50: 0.000023 mM
2-[(cyclopentylcarbonyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
32% inhibition at 0.01 mM
2-[(methanesulfonyl)amino]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzamide
-
inhibitor identified in silico, displays significant inhibition of both Leishmania donovani and Trypanosoma brucei
2-[(methanesulfonyl)amino]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzamide
-
inhibitor identified in silico, displays significant inhibition of both Leishmania donovani and Trypanosoma brucei
2-[([(1R,3S)-3-[(1-benzofuran-5-ylmethyl)amino]cyclohexyl]acetyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
2-[([(1R,3S)-3-[(1-benzofuran-5-ylmethyl)amino]cyclohexyl]acetyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
2-[([(1R,3S)-3-[(1-benzofuran-5-ylmethyl)amino]cyclohexyl]acetyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
-
2-[([(1R,3S)-3-[(1-benzofuran-6-ylmethyl)amino]cyclohexyl]acetyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
2-[([(1R,3S)-3-[(1-benzofuran-6-ylmethyl)amino]cyclohexyl]acetyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
2-[([(1R,3S)-3-[(1-benzofuran-6-ylmethyl)amino]cyclohexyl]acetyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
-
2-[([(1R,3S)-3-[(1-benzofuran-6-ylmethyl)amino]cyclohexyl]carbonyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
-
2-[([(1R,3S)-3-[(1-benzofuran-6-ylmethyl)amino]cyclohexyl]carbonyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
-
2-[([(1R,3S)-3-[(1-benzofuran-6-ylmethyl)amino]cyclohexyl]carbonyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
-
2-[([(1R,3S)-3-[(1-benzofuran-6-ylmethyl)amino]cyclohexyl]carbonyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
-
2-[([(1R,3S)-3-[(1-benzofuran-6-ylmethyl)amino]cyclohexyl]carbonyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
-
2-[([(1R,3S)-3-[(1-benzofuran-6-ylmethyl)amino]cyclohexyl]carbonyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
-
2-[([(1R,3S)-3-[(1-benzofuran-6-ylmethyl)amino]cyclohexyl]carbonyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
-
2-[([(1R,3S)-3-[(1H-indol-5-ylmethyl)amino]cyclohexyl]acetyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
2-[([(1R,3S)-3-[(1H-indol-5-ylmethyl)amino]cyclohexyl]acetyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
2-[([(1R,3S)-3-[(1H-indol-5-ylmethyl)amino]cyclohexyl]acetyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
-
2-[([(1R,3S)-3-[(1H-indol-6-ylmethyl)amino]cyclohexyl]acetyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
-
2-[([(1R,3S)-3-[(1H-indol-6-ylmethyl)amino]cyclohexyl]acetyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
-
2-[([(1R,3S)-3-[(1H-indol-6-ylmethyl)amino]cyclohexyl]acetyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
-
2-[([(1R,3S)-3-[(1H-indol-6-ylmethyl)amino]cyclohexyl]acetyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
-
2-[([(1R,3S)-3-[(1H-indol-6-ylmethyl)amino]cyclohexyl]acetyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
-
2-[([(1R,3S)-3-[(1H-indol-6-ylmethyl)amino]cyclohexyl]acetyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
-
2-[([(1R,3S)-3-[(1H-indol-6-ylmethyl)amino]cyclohexyl]acetyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
-
2-[[(2,5-dimethoxyphenyl)carbonyl]amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
IC50: 0.00031 mM
2-[[(2,5-dimethoxyphenyl)carbonyl]amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
71% inhibition at 0.01 mM
2-[[(2-chloropyridin-3-yl)carbonyl]amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
IC50: above 0.01 mM
2-[[(2-chloropyridin-3-yl)carbonyl]amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
16% inhibition at 0.01 mM
2-[[(3,4-dichlorophenyl)carbonyl]amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
IC50: above 0.01 mM
2-[[(3,4-dichlorophenyl)carbonyl]amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
22% inhibition at 0.01 mM
2-[[(4-chlorophenyl)carbonyl]amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
IC50: above 0.01 mM
2-[[(4-chlorophenyl)carbonyl]amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
8% inhibition at 0.01 mM
3,3'-[(3-carboxy-4-oxocyclohexa-2,5-dien-1-ylidene)methanediyl]bis(6-hydroxybenzoic acid)
-
-
3,3'-[(3-carboxy-4-oxocyclohexa-2,5-dien-1-ylidene)methanediyl]bis(6-hydroxybenzoic acid)
-
-
3,3'-[(3-carboxy-4-oxocyclohexa-2,5-dien-1-ylidene)methanediyl]bis(6-hydroxybenzoic acid)
-
-
3,3'-[(3-carboxy-4-oxocyclohexa-2,5-dien-1-ylidene)methanediyl]bis(6-hydroxybenzoic acid)
-
-
3,3'-[(3-carboxy-4-oxocyclohexa-2,5-dien-1-ylidene)methanediyl]bis(6-hydroxybenzoic acid)
-
3,3'-[(3-carboxy-4-oxocyclohexa-2,5-dien-1-ylidene)methanediyl]bis(6-hydroxybenzoic acid)
-
-
3,3'-[(3-carboxy-4-oxocyclohexa-2,5-dien-1-ylidene)methanediyl]bis(6-hydroxybenzoic acid)
-
3,3'-[(3-carboxy-4-oxocyclohexa-2,5-dien-1-ylidene)methanediyl]bis(6-hydroxybenzoic acid)
-
-
3,3'-[(3-carboxy-4-oxocyclohexa-2,5-dien-1-ylidene)methanediyl]bis(6-hydroxybenzoic acid)
-
-
3-(methyl[6-methyl-2-[methyl(1-methylpiperidin-4-yl)amino]thieno[3,2-d]pyrimidin-4-yl]amino)propanenitrile
-
3-(methyl[6-methyl-2-[methyl(1-methylpiperidin-4-yl)amino]thieno[3,2-d]pyrimidin-4-yl]amino)propanenitrile
-
3-(methyl[6-methyl-2-[methyl(1-methylpiperidin-4-yl)amino]thieno[3,2-d]pyrimidin-4-yl]amino)propanenitrile
-
3-(methyl[6-methyl-2-[methyl(1-methylpiperidin-4-yl)amino]thieno[3,2-d]pyrimidin-4-yl]amino)propanenitrile
-
3-([3-methyl-2-[(2,3,4-trifluorophenoxy)methyl]-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)propan-1-amine
-
-
3-([3-methyl-2-[(2,3,4-trifluorophenoxy)methyl]-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)propan-1-amine
-
-
3-([3-methyl-2-[(2,3,4-trifluorophenoxy)methyl]-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)propan-1-amine
-
-
3-([3-methyl-2-[(2,3,4-trifluorophenoxy)methyl]-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)propan-1-amine
-
-
3-([3-methyl-2-[(2,3,4-trifluorophenoxy)methyl]-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)propan-1-amine
-
-
3-([3-methyl-2-[(2,3,4-trifluorophenoxy)methyl]-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)propan-1-amine
-
-
3-([3-methyl-2-[(2,3,4-trifluorophenoxy)methyl]-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)propan-1-amine
-
-
3-([3-methyl-2-[(2,3,4-trifluorophenoxy)methyl]-1-benzofuran-4-yl]oxy)-N-[(pyridin-3-yl)methyl]propan-1-amine
compound displays hydrogen bonds between the benzofuran oxygen and the His227 residues as well as between the nitrogen from 2-piridinyl ring at C4 side chain and the Tyr119. The 2-pyridinyl ring interacts with Phe117 as well as the trifluorobenzene, at C2 side chain, interacts both with Phe115 and Phe240
3-([3-methyl-2-[(2,3,4-trifluorophenoxy)methyl]-1-benzofuran-4-yl]oxy)-N-[(pyridin-3-yl)methyl]propan-1-amine
compound displays between the nitrogen from the C6 side chain of BF and both Leu421 carboxylic oxygens as well as with the Tyr92 aromatic hydroxy group. Pi-stacking interactions are observed between the aromatic ring from C2 side chain and Phe232 and between the benzofuran ring and Phe90
4-(4,5-dihydroxy-9-methyl-3-oxo-1,3,3a,4,9,9a-hexahydronaphtho[2,3-c]furan-1-yl)-2,5,6-trihydroxycyclohexa-2,4-diene-1-carboxamide
-
-
4-(4,5-dihydroxy-9-methyl-3-oxo-1,3,3a,4,9,9a-hexahydronaphtho[2,3-c]furan-1-yl)-2,5,6-trihydroxycyclohexa-2,4-diene-1-carboxamide
-
-
4-(4,5-dihydroxy-9-methyl-3-oxo-1,3,3a,4,9,9a-hexahydronaphtho[2,3-c]furan-1-yl)-2,5,6-trihydroxycyclohexa-2,4-diene-1-carboxamide
-
-
4-(4,5-dihydroxy-9-methyl-3-oxo-1,3,3a,4,9,9a-hexahydronaphtho[2,3-c]furan-1-yl)-2,5,6-trihydroxycyclohexa-2,4-diene-1-carboxamide
-
-
4-(4,5-dihydroxy-9-methyl-3-oxo-1,3,3a,4,9,9a-hexahydronaphtho[2,3-c]furan-1-yl)-2,5,6-trihydroxycyclohexa-2,4-diene-1-carboxamide
-
-
4-(4,5-dihydroxy-9-methyl-3-oxo-1,3,3a,4,9,9a-hexahydronaphtho[2,3-c]furan-1-yl)-2,5,6-trihydroxycyclohexa-2,4-diene-1-carboxamide
-
-
4-(4,5-dihydroxy-9-methyl-3-oxo-1,3,3a,4,9,9a-hexahydronaphtho[2,3-c]furan-1-yl)-2,5,6-trihydroxycyclohexa-2,4-diene-1-carboxamide
-
-
4-(4,5-dihydroxy-9-methyl-3-oxo-1,3,3a,4,9,9a-hexahydronaphtho[2,3-c]furan-1-yl)-2,5-dihydroxybenzamide
-
4-(4,5-dihydroxy-9-methyl-3-oxo-1,3,3a,4,9,9a-hexahydronaphtho[2,3-c]furan-1-yl)-2,5-dihydroxybenzamide
-
4-(4,5-dihydroxy-9-methyl-3-oxo-1,3,3a,4,9,9a-hexahydronaphtho[2,3-c]furan-1-yl)-2,5-dihydroxybenzamide
-
-
4-methyl-N-[2-[(7-methylthieno[3,2-d]pyrimidin-4-yl)sulfanyl]phenyl]benzene-1-sulfonamide
-
inhibitor identified in silico, displays significant inhibition of both Leishmania donovani and Trypanosoma brucei
4-methyl-N-[2-[(7-methylthieno[3,2-d]pyrimidin-4-yl)sulfanyl]phenyl]benzene-1-sulfonamide
-
inhibitor identified in silico, displays significant inhibition of both Leishmania donovani and Trypanosoma brucei
4-[(2-[5-[(1,3,5-trimethyl-1H-pyrazol-4-yl)methyl]-1,3,4-oxadiazol-2-yl]-1-benzothiophen-3-yl)oxy]piperidine
-
selective and high affinity Plasmodium falciparum inhibitor, pKi value for human enzyme 7.22
4-[(2-[5-[(1,3,5-trimethyl-1H-pyrazol-4-yl)methyl]-1,3,4-oxadiazol-2-yl]-1-benzothiophen-3-yl)oxy]piperidine
-
selective and high affinity inhibitor, pKi value 8.10
5-chloro-2-[[4-(3,5-difluorophenyl)piperidin-1-yl]methyl]-1-methyl-1H-benzimidazole
-
5-chloro-2-[[4-(3,5-difluorophenyl)piperidin-1-yl]methyl]-1-methyl-1H-benzimidazole
-
5-chloro-2-[[4-(3,5-difluorophenyl)piperidin-1-yl]methyl]-1-methyl-1H-benzimidazole
-
5-chloro-2-[[4-(3,5-difluorophenyl)piperidin-1-yl]methyl]-1-methyl-1H-benzimidazole
-
5-chloro-N-[4-(4-fluorophenoxy)phenyl]-1,3-dimethyl-1H-pyrazole-4-sulfonamide
-
inhibitor identified in silico, displays significant inhibition of both Leishmania donovani and Trypanosoma brucei
5-chloro-N-[4-(4-fluorophenoxy)phenyl]-1,3-dimethyl-1H-pyrazole-4-sulfonamide
-
inhibitor identified in silico, displays significant inhibition of both Leishmania donovani and Trypanosoma brucei
5-methyl-N-[(5-methyl-3-phenyl-1,2-oxazol-4-yl)methyl]-1-phenyl-1H-pyrazole-4-sulfonamide
-
inhibitor identified in silico, displays significant inhibition of both Leishmania donovani and Trypanosoma brucei
5-methyl-N-[(5-methyl-3-phenyl-1,2-oxazol-4-yl)methyl]-1-phenyl-1H-pyrazole-4-sulfonamide
-
inhibitor identified in silico, displays significant inhibition of both Leishmania donovani and Trypanosoma brucei
cis-4-[(naphthalen-2-ylmethyl)amino]-N-(6-pyridin-2-yl-1,3-benzothiazol-2-yl)cyclohexanecarboxamide
-
-
cis-4-[(naphthalen-2-ylmethyl)amino]-N-(6-pyridin-2-yl-1,3-benzothiazol-2-yl)cyclohexanecarboxamide
-
-
cis-4-[(naphthalen-2-ylmethyl)amino]-N-(6-pyridin-2-yl-1,3-benzothiazol-2-yl)cyclohexanecarboxamide
-
-
cis-4-[(naphthalen-2-ylmethyl)amino]-N-(6-pyridin-2-yl-1,3-benzothiazol-2-yl)cyclohexanecarboxamide
-
-
cis-4-[(naphthalen-2-ylmethyl)amino]-N-(6-pyridin-2-yl-1,3-benzothiazol-2-yl)cyclohexanecarboxamide
-
cis-4-[(naphthalen-2-ylmethyl)amino]-N-(6-pyridin-2-yl-1,3-benzothiazol-2-yl)cyclohexanecarboxamide
-
-
cis-4-[(naphthalen-2-ylmethyl)amino]-N-(6-pyridin-2-yl-1,3-benzothiazol-2-yl)cyclohexanecarboxamide
-
cis-4-[(naphthalen-2-ylmethyl)amino]-N-(6-pyridin-2-yl-1,3-benzothiazol-2-yl)cyclohexanecarboxamide
-
-
cis-4-[(naphthalen-2-ylmethyl)amino]-N-(6-pyridin-2-yl-1,3-benzothiazol-2-yl)cyclohexanecarboxamide
-
-
cis-N-(6-fluoro-1,3-benzothiazol-2-yl)-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
-
cis-N-(6-fluoro-1,3-benzothiazol-2-yl)-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
-
cis-N-(6-fluoro-1,3-benzothiazol-2-yl)-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
-
cis-N-(6-fluoro-1,3-benzothiazol-2-yl)-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
-
cis-N-(6-fluoro-1,3-benzothiazol-2-yl)-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
cis-N-(6-fluoro-1,3-benzothiazol-2-yl)-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
-
cis-N-(6-fluoro-1,3-benzothiazol-2-yl)-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
cis-N-(6-fluoro-1,3-benzothiazol-2-yl)-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
-
cis-N-(6-fluoro-1,3-benzothiazol-2-yl)-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
-
cis-N-1,3-benzothiazol-2-yl-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
-
cis-N-1,3-benzothiazol-2-yl-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
-
cis-N-1,3-benzothiazol-2-yl-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
-
cis-N-1,3-benzothiazol-2-yl-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
-
cis-N-1,3-benzothiazol-2-yl-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
cis-N-1,3-benzothiazol-2-yl-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
-
cis-N-1,3-benzothiazol-2-yl-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
cis-N-1,3-benzothiazol-2-yl-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
-
cis-N-1,3-benzothiazol-2-yl-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
-
CP-014553
-
CP-030890-27
-
CP-030890-27
IC50: 250 nM
DDD85646
-
-
enolase
-
-
ethyl 1-[4-[(4-methoxybenzene-1-sulfonyl)amino]phenyl]-3,5-dimethyl-1H-pyrazole-4-carboxylate
-
inhibitor identified in silico, displays significant inhibition of both Leishmania donovani and Trypanosoma brucei
ethyl 1-[4-[(4-methoxybenzene-1-sulfonyl)amino]phenyl]-3,5-dimethyl-1H-pyrazole-4-carboxylate
-
inhibitor identified in silico, displays significant inhibition of both Leishmania donovani and Trypanosoma brucei
ethyl 3-methyl-4-[3-[(pyridin-3-ylmethyl)amino]propoxy]-1-benzofuran-2-carboxylate
-
-
ethyl 3-methyl-4-[3-[(pyridin-3-ylmethyl)amino]propoxy]-1-benzofuran-2-carboxylate
-
-
ethyl 3-methyl-4-[3-[(pyridin-3-ylmethyl)amino]propoxy]-1-benzofuran-2-carboxylate
-
-
ethyl 3-methyl-4-[3-[(pyridin-3-ylmethyl)amino]propoxy]-1-benzofuran-2-carboxylate
-
-
ethyl 3-methyl-4-[3-[(pyridin-3-ylmethyl)amino]propoxy]-1-benzofuran-2-carboxylate
-
-
ethyl 3-methyl-4-[3-[(pyridin-3-ylmethyl)amino]propoxy]-1-benzofuran-2-carboxylate
-
-
ethyl 3-methyl-4-[3-[(pyridin-3-ylmethyl)amino]propoxy]-1-benzofuran-2-carboxylate
-
-
ethyl 4-(ethylsulfanyl)-6-([6-[(piperidin-4-yl)amino]pyridin-3-yl]methoxy)quinoline-3-carboxylate
-
ethyl 4-(ethylsulfanyl)-6-([6-[(piperidin-4-yl)amino]pyridin-3-yl]methoxy)quinoline-3-carboxylate
-
-
ethyl 4-(ethylsulfanyl)-6-([6-[(piperidin-4-yl)amino]pyridin-3-yl]methoxy)quinoline-3-carboxylate
-
ethyl 4-(ethylsulfanyl)-6-[(6-[[(3R)-pyrrolidin-3-yl]amino]pyridin-3-yl)methoxy]quinoline-3-carboxylate
-
ethyl 4-(ethylsulfanyl)-6-[(6-[[(3R)-pyrrolidin-3-yl]amino]pyridin-3-yl)methoxy]quinoline-3-carboxylate
-
-
ethyl 4-(ethylsulfanyl)-6-[(6-[[(3R)-pyrrolidin-3-yl]amino]pyridin-3-yl)methoxy]quinoline-3-carboxylate
-
ethyl 4-(ethylsulfanyl)-6-[[6-(piperazin-1-yl)pyridin-3-yl]methoxy]quinoline-3-carboxylate
-
ethyl 4-(ethylsulfanyl)-6-[[6-(piperazin-1-yl)pyridin-3-yl]methoxy]quinoline-3-carboxylate
-
-
ethyl 4-(ethylsulfanyl)-6-[[6-(piperazin-1-yl)pyridin-3-yl]methoxy]quinoline-3-carboxylate
-
ethyl 4-[(2-cyanoethyl)sulfanyl]-6-[[6-(piperazin-1-yl)pyridin-3-yl]methoxy]quinoline-3-carboxylate
-
ethyl 4-[(2-cyanoethyl)sulfanyl]-6-[[6-(piperazin-1-yl)pyridin-3-yl]methoxy]quinoline-3-carboxylate
-
-
ethyl 4-[(2-cyanoethyl)sulfanyl]-6-[[6-(piperazin-1-yl)pyridin-3-yl]methoxy]quinoline-3-carboxylate
-
ethyl 6-(benzyloxy)-4-(ethylsulfanyl)quinoline-3-carboxylate
-
ethyl 6-(benzyloxy)-4-(ethylsulfanyl)quinoline-3-carboxylate
-
-
ethyl 6-(benzyloxy)-4-(ethylsulfanyl)quinoline-3-carboxylate
-
ethyl 6-([6-[(2-aminoethyl)amino]pyridin-3-yl]methoxy)-4-(ethylsulfanyl)quinoline-3-carboxylate
-
ethyl 6-([6-[(2-aminoethyl)amino]pyridin-3-yl]methoxy)-4-(ethylsulfanyl)quinoline-3-carboxylate
-
-
ethyl 6-([6-[(2-aminoethyl)amino]pyridin-3-yl]methoxy)-4-(ethylsulfanyl)quinoline-3-carboxylate
-
ethyl 6-([6-[(3-aminopropyl)amino]pyridin-3-yl]methoxy)-4-(ethylsulfanyl)quinoline-3-carboxylate
-
ethyl 6-([6-[(3-aminopropyl)amino]pyridin-3-yl]methoxy)-4-(ethylsulfanyl)quinoline-3-carboxylate
-
-
ethyl 6-([6-[(3-aminopropyl)amino]pyridin-3-yl]methoxy)-4-(ethylsulfanyl)quinoline-3-carboxylate
-
factor NIP71
bovine brain inhibitor protein
-
factor NIP71
-
competitive against activation factor NAF45
-
factor NIP71
-
bovine brain inhibitor protein; strong inhibition in a concentration dependent manner, noncompetitive
-
heat shock cognate protein 70
-
involved in NMT1 regulation, overview
-
heat shock cognate protein 70
involved in NMT1 regulation, overview; involved in NMT1 regulation, overview
-
N,N-dimethyl-1-[5-(2-methylphenyl)-1H-indazol-3-yl]methanamine
-
N,N-dimethyl-1-[5-(2-methylphenyl)-1H-indazol-3-yl]methanamine
-
N,N-dimethyl-1-[5-(2-methylphenyl)-1H-indazol-3-yl]methanamine
-
N,N-dimethyl-1-[5-(2-methylphenyl)-1H-indazol-3-yl]methanamine
-
N-(10-aminodecanoyl)-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide
peptidomimetic inhibitor
N-(10-aminodecanoyl)-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide
peptidomimetic inhibitor
N-(10-aminodecanoyl)-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide
-
peptidomimetic inhibitor
N-(10-aminodecanoyl)-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide
peptidomimetic inhibitor
N-(6-[[N-(naphthalen-2-ylmethyl)-b-alanyl]amino]-1,3-benzothiazol-2-yl)cyclohexanecarboxamide
IC50: 0.00018 mM
N-(6-[[N-(naphthalen-2-ylmethyl)-b-alanyl]amino]-1,3-benzothiazol-2-yl)cyclohexanecarboxamide
32% inhibition at 0.01 mM
N-(6-[[N-(naphthalen-2-ylmethyl)glycyl]amino]-1,3-benzothiazol-2-yl)cyclohexanecarboxamide
IC50: 0.0023 mM
N-(6-[[N-(naphthalen-2-ylmethyl)glycyl]amino]-1,3-benzothiazol-2-yl)cyclohexanecarboxamide
8% inhibition at 0.01 mM
N-([4-[5-(2-methyl-1H-imidazol-1-yl)pentyl]phenyl]acetyl)-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide
-
-
N-([4-[5-(2-methyl-1H-imidazol-1-yl)pentyl]phenyl]acetyl)-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide
-
-
N-([4-[5-(2-methyl-1H-imidazol-1-yl)pentyl]phenyl]acetyl)-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide
-
-
N-([4-[5-(2-methyl-1H-imidazol-1-yl)pentyl]phenyl]acetyl)-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide
-
-
N-([4-[5-(2-methyl-1H-imidazol-1-yl)pentyl]phenyl]acetyl)-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide
-
-
N-([4-[5-(2-methyl-1H-imidazol-1-yl)pentyl]phenyl]acetyl)-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide
-
-
N-([4-[5-(2-methyl-1H-imidazol-1-yl)pentyl]phenyl]acetyl)-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide
-
-
N-[(1R)-1-[3-(3-aminopropyl)-4-(2-cyclohexylethoxy)benzyl]-2-hydroxyethyl]-2-[4-[4-(2-methyl-1H-imidazol-1-yl)butyl]phenyl]acetamide
-
-
N-[(1R)-1-[3-(3-aminopropyl)-4-(2-cyclohexylethoxy)benzyl]-2-hydroxyethyl]-2-[4-[4-(2-methyl-1H-imidazol-1-yl)butyl]phenyl]acetamide
-
-
N-[(1R)-1-[3-(3-aminopropyl)-4-(2-cyclohexylethoxy)benzyl]-2-hydroxyethyl]-2-[4-[4-(2-methyl-1H-imidazol-1-yl)butyl]phenyl]acetamide
-
-
N-[(1R)-1-[3-(3-aminopropyl)-4-(2-cyclohexylethoxy)benzyl]-2-hydroxyethyl]-2-[4-[4-(2-methyl-1H-imidazol-1-yl)butyl]phenyl]acetamide
-
-
N-[(1R)-1-[3-(3-aminopropyl)-4-(2-cyclohexylethoxy)benzyl]-2-hydroxyethyl]-2-[4-[4-(2-methyl-1H-imidazol-1-yl)butyl]phenyl]acetamide
-
-
N-[(1R)-1-[3-(3-aminopropyl)-4-(2-cyclohexylethoxy)benzyl]-2-hydroxyethyl]-2-[4-[4-(2-methyl-1H-imidazol-1-yl)butyl]phenyl]acetamide
-
-
N-[(1R)-1-[3-(3-aminopropyl)-4-(2-cyclohexylethoxy)benzyl]-2-hydroxyethyl]-2-[4-[4-(2-methyl-1H-imidazol-1-yl)butyl]phenyl]acetamide
-
-
N-[(3R)-1-(N-methylglycyl)pyrrolidin-3-yl]-2-(trifluoromethyl)benzamide
-
N-[(3R)-1-(N-methylglycyl)pyrrolidin-3-yl]-2-(trifluoromethyl)benzamide
-
N-[(3R)-1-(N-methylglycyl)pyrrolidin-3-yl]-2-(trifluoromethyl)benzamide
-
N-[(3R)-1-(N-methylglycyl)pyrrolidin-3-yl]-2-(trifluoromethyl)benzamide
-
N-[(pyridin-3-yl)methyl]-3-([2-[(2,3,4-trifluorophenoxy)methyl]-1,3-benzothiazol-7-yl]oxy)propan-1-amine
compound forms hydrogen bonds between the nitrogen from C4 side chain and the Leu421 as well as between the benzothiazole nitrogen and His227
N-[(pyridin-3-yl)methyl]-3-([2-[(2,3,4-trifluorophenoxy)methyl]-1,3-benzothiazol-7-yl]oxy)propan-1-amine
the nitrogen from the C6 side chain forms hydrogen bonds with both carboxylate oxygens of Leu421. His219 interacts through hydrogen bonds with the oxygen from the C2 side chain as well as the nitrogen from benzothiazole ring with His219
N-[2-chloro-5-[(3S,4R)-1-[4-(4-chlorophenyl)-3-hydroxybutanoyl]-4-(hydroxymethyl)pyrrolidin-3-yl]phenyl]-2-(4-fluorophenyl)acetamide
inhibitor shows good selectiviy over the human enzyme
N-[2-chloro-5-[(3S,4R)-1-[4-(4-chlorophenyl)-3-hydroxybutanoyl]-4-(hydroxymethyl)pyrrolidin-3-yl]phenyl]-2-(4-fluorophenyl)acetamide
inhibitor shows good selectiviy over the human enzyme
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-(propanoylamino)-1,3-benzothiazole-6-carboxamide
IC50: 0.00013 mM
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-(propanoylamino)-1,3-benzothiazole-6-carboxamide
4% inhibition at 0.01 mM
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-([[4-(trifluoromethyl)phenyl]carbonyl]amino)-1,3-benzothiazole-6-carboxamide
IC50: above 0.01 mM
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-([[4-(trifluoromethyl)phenyl]carbonyl]amino)-1,3-benzothiazole-6-carboxamide
1% inhibition at 0.01 mM
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-[(phenylcarbonyl)amino]-1,3-benzothiazole-6-carboxamide
IC50: 0.00016 mM
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-[(phenylcarbonyl)amino]-1,3-benzothiazole-6-carboxamide
32% inhibition at 0.01 mM
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-[(pyrazin-2-ylcarbonyl)amino]-1,3-benzothiazole-6-carboxamide
IC50: 0.00073 mM
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-[(pyrazin-2-ylcarbonyl)amino]-1,3-benzothiazole-6-carboxamide
11% inhibition at 0.01 mM
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-[(pyridin-2-ylcarbonyl)amino]-1,3-benzothiazole-6-carboxamide
IC50: above 0.01 mM
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-[(pyridin-2-ylcarbonyl)amino]-1,3-benzothiazole-6-carboxamide
37% inhibition at 0.01 mM
N-[5-[(4R)-1-[(3R)-3-amino-4-(4-chlorophenyl)butanoyl]-4-(hydroxymethyl)pyrrolidin-3-yl]-2-chlorophenyl]-2-(4-fluorophenyl)acetamide
inhibitor shows good selectiviy over the human enzyme
N-[5-[(4R)-1-[(3R)-3-amino-4-(4-chlorophenyl)butanoyl]-4-(hydroxymethyl)pyrrolidin-3-yl]-2-chlorophenyl]-2-(4-fluorophenyl)acetamide
inhibitor shows good selectiviy over the human enzyme
N-[6-([3-[(naphthalen-2-ylmethyl)amino]azetidin-1-yl]carbonyl)-1,3-benzothiazol-2-yl]cyclohexanecarboxamide
IC50: 0.000065 mM
N-[6-([3-[(naphthalen-2-ylmethyl)amino]azetidin-1-yl]carbonyl)-1,3-benzothiazol-2-yl]cyclohexanecarboxamide
14% inhibition at 0.01 mM
N-[6-([3-[(naphthalen-2-ylmethyl)amino]piperidin-1-yl]carbonyl)-1,3-benzothiazol-2-yl]cyclohexanecarboxamide
IC50: 0.00021 mM
N-[6-([3-[(naphthalen-2-ylmethyl)amino]piperidin-1-yl]carbonyl)-1,3-benzothiazol-2-yl]cyclohexanecarboxamide
27% inhibition at 0.01 mM
N-[6-([3-[(naphthalen-2-ylmethyl)amino]pyrrolidin-1-yl]carbonyl)-1,3-benzothiazol-2-yl]cyclohexanecarboxamide
IC50: 0.00019 mM
N-[6-([3-[(naphthalen-2-ylmethyl)amino]pyrrolidin-1-yl]carbonyl)-1,3-benzothiazol-2-yl]cyclohexanecarboxamide
36% inhibition at 0.01 mM
N-[6-([4-[(naphthalen-2-ylmethyl)amino]piperidin-1-yl]carbonyl)-1,3-benzothiazol-2-yl]cyclohexanecarboxamide
IC50: 0.0005 mM
N-[6-([4-[(naphthalen-2-ylmethyl)amino]piperidin-1-yl]carbonyl)-1,3-benzothiazol-2-yl]cyclohexanecarboxamide
27% inhibition at 0.01 mM
N-[6-[(4-[[(naphthalen-2-ylmethyl)amino]methyl]piperidin-1-yl)carbonyl]-1,3-benzothiazol-2-yl]cyclohexanecarboxamide
IC50: 0.000026 mM
N-[6-[(4-[[(naphthalen-2-ylmethyl)amino]methyl]piperidin-1-yl)carbonyl]-1,3-benzothiazol-2-yl]cyclohexanecarboxamide
32% inhibition at 0.01 mM
N-[[3'-(6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-5(4H)-ylmethyl)biphenyl-3-yl]methyl]-2-(pyridin-3-yl)ethanamine
-
N-[[3'-(6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-5(4H)-ylmethyl)biphenyl-3-yl]methyl]-2-(pyridin-3-yl)ethanamine
-
N-[[3'-(6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-5(4H)-ylmethyl)biphenyl-3-yl]methyl]-2-(pyridin-3-yl)ethanamine
-
N-[[3'-(6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-5(4H)-ylmethyl)biphenyl-3-yl]methyl]-2-(pyridin-3-yl)ethanamine
-
palmitoyl-CoA
-
S-(2-Oxo)-pentadecyl-CoA
-
strong
S-(2-Oxo)-pentadecyl-CoA
-
-
S-(2-Oxo)-pentadecyl-CoA
-
competitive
S-(2-Oxo)-pentadecyl-CoA
-
S-(2-Oxo)-pentadecyl-CoA
-
-
S-(2-oxo)pentadecyl-CoA
-
-
S-(2-oxo)pentadecyl-CoA
-
-
S-(2-oxo)pentadecyl-CoA
-
-
S-(2-oxo)pentadecyl-CoA
i.e. NHM, a non-hydrolysable myristoyl-CoA analogue, binding structure analysis, overview; i.e. NHM, a non-hydrolysable myristoyl-CoA analogue, binding structure, overview
S-(2-oxo)pentadecyl-CoA
-
-
S-(2-oxo)pentadecyl-CoA
-
-
S-(2-oxo)pentadecyl-CoA
-
-
S-(2-oxo)pentadecyl-CoA
-
-
SC-58272
-
-
SC-58272
-
peptidomimetic derived from the N-terminal sequence of the substrate ADP-ribosylation factor-2, i.e. Arf2p
[4-[3-(benzylamino)propoxy]-3-methyl-1-benzofuran-2-yl](1-methyl-1H-imidazol-2-yl)methanone
-
[4-[3-(benzylamino)propoxy]-3-methyl-1-benzofuran-2-yl](1-methyl-1H-imidazol-2-yl)methanone
-
[4-[3-(benzylamino)propoxy]-3-methyl-1-benzofuran-2-yl](1-methyl-1H-imidazol-2-yl)methanone
-
additional information
-
inhibition mechanism; inhibitor binding site
-
additional information
-
inhibitor design and development, overview
-
additional information
inhibitor design and three-dimensional quantitative structure-activity relationship analysis, modelling, detailed overview
-
additional information
-
inhibitor design and development, overview
-
additional information
-
inhibitor design and development, overview
-
additional information
-
inhibition mechanism
-
additional information
development of specific anti-protozoan inhibitors against NMT, specificity over the human isozymes, component screening, structure-activity relationships, overview; development of specific anti-protozoan inhibitors against NMT, specificity over the human isozymes, component screening, structure-activity relationships, overview
-
additional information
development of specific anti-protozoan inhibitors against NMT, specificity over the human isozymes, component screening, structure-activity relationships, overview; development of specific anti-protozoan inhibitors against NMT, specificity over the human isozymes, component screening, structure-activity relationships, overview
-
additional information
-
development of specific anti-protozoan inhibitors against NMT, specificity over the human isozymes, component screening, structure-activity relationships, overview; development of specific anti-protozoan inhibitors against NMT, specificity over the human isozymes, component screening, structure-activity relationships, overview
-
additional information
-
2D and 3D quantitative structure-activity relationship (QSAR) studies on a series of benzothiophene derivatives as Plasmodium falciparum NMT and human NMT inhibitors. The polar interactions (electrostatic and hydrogen-bonding properties) as the major molecular features that affected the inhibitory activity and selectivity
-
additional information
ligand binding structure-function analysis for drug design, overview
-
additional information
-
ligand binding structure-function analysis for drug design, overview
-
additional information
development of specific anti-protozoan inhibitors against NMT, specificity over the human isozymes, component screening, structure-activity relationships, overview
-
additional information
-
development of specific anti-protozoan inhibitors against NMT, specificity over the human isozymes, component screening, structure-activity relationships, overview
-
additional information
-
inhibitor design and development, overview
-
additional information
binding mode, structure-activity relationship and selectivity of inhibitors, overview. The enzyme is a target for rational inhibitor design, modelling of inhibitor docking, overview
-
additional information
-
binding mode, structure-activity relationship and selectivity of inhibitors, overview. The enzyme is a target for rational inhibitor design, modelling of inhibitor docking, overview
-
additional information
-
-
-
additional information
-
no inhibition by 10 mM EDTA
-
additional information
-
-
-
additional information
-
inhibitor design and development, overview
-
additional information
binding mode, structure-activity relationship and selectivity of inhibitors, overview. The enzyme is a target for rational inhibitor design, modelling of inhibitor docking, overview
-
additional information
-
binding mode, structure-activity relationship and selectivity of inhibitors, overview. The enzyme is a target for rational inhibitor design, modelling of inhibitor docking, overview
-
additional information
development of specific anti-protozoan inhibitors against NMT, specificity over the human isozymes, component screening, structure-activity relationships, overview
-
additional information
-
development of specific anti-protozoan inhibitors against NMT, specificity over the human isozymes, component screening, structure-activity relationships, overview
-
additional information
-
2D and 3D quantitative structure-activity relationship (QSAR) studies on a series of benzothiophene derivatives as Plasmodium falciparum NMT and human NMT inhibitors. The polar interactions (electrostatic and hydrogen-bonding properties) as the major molecular features that affected the inhibitory activity and selectivity
-
additional information
-
NMT inhibitors: screening, synthesis, and structural characterization of their binding mode, overview
-
additional information
-
-
-
additional information
-
inhibitory peptides
-
additional information
-
-
-
additional information
-
overview: inhibition by glycylpeptides with varying amino acids at positions 2 to 8
-
additional information
-
inhibitory peptides
-
additional information
-
inhibitor design and development, overview
-
additional information
-
inhibitor design and development, overview
-
additional information
-
binding mode, structure-activity relationship and selectivity of inhibitors, overview. The enzyme is a target for rational inhibitor design, modelling of inhibitor docking, overview
-
additional information
development of specific anti-protozoan inhibitors against NMT, specificity over the human isozymes, component screening, structure-activity relationships, overview
-
additional information
-
development of specific anti-protozoan inhibitors against NMT, specificity over the human isozymes, component screening, structure-activity relationships, overview
-
additional information
-
development of inhibitors based on DDD85646
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.00000049
(1R,3S)-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
Candida albicans
IC50: 0.00000049 mM
0.000015
(1R,3S)-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclopentanecarboxamide
Candida albicans
IC50: 0.000015 mM
0.00000049
(1R,3S)-N-{2-[(cyclopeanthylcarbonyl)amino]-benzothiazol-6-yl}-3-[(2-naphthylmethyl) amino] cyclohexanecarboxamide
Candida albicans
competitive with the substrate peptide and non-competitive with myristoyl-CoA. IC50: 0.49 nM
0.00001
(1S,3R)-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
Candida albicans
IC50: above 0.00001 mM
0.000011
(1S,3R)-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclopentanecarboxamide
Candida albicans
IC50: 0.000011mM
100
1,12-dodecanedicarboxylic acid
Homo sapiens
IC50 above 100 mM
100
1,3-dimyristoylglycerol
Homo sapiens
IC50 above 100 mM
0.0001
1-(4-(3,5-dichloro-4-((2-methylpyridin-3-yl)methoxy)phenyl)pyridin-2-yl)piperazine
Trypanosoma brucei
-
pH 7.4, 22°C
0.00008
1-(4-(3,5-dichloro-4-((2-phenylpyridin-3-yl)methoxy)phenyl)-pyridin-2-yl)piperazine
Trypanosoma brucei
-
pH 7.4, 22°C
0.00002 - 0.0001
1-(4-(3,5-dichloro-4-(pyridin-2-ylmethoxy)phenyl)pyridin-2-yl)-piperazine
0.000001
1-(5-[3,4-difluoro-2-[2-(1,3,5-trimethyl-1H-pyrazol-4-yl)ethoxy]phenyl]-1-methyl-1H-indazol-3-yl)-N,N-dimethylmethanamine
Homo sapiens
IC50 value below 1 nM, pH not specified in the publication, temperature not specified in the publication
0.0086
1-acetyl-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)-2,3-dihydro-1H-indole-5-sulfonamide
Trypanosoma brucei
-
pH 7.4, 22°C
1 - 100
1-myristoyl-rac-glycerol
Homo sapiens
IC50 in the range 1-100 mM
1 - 100
1-Tetradecanal
Homo sapiens
IC50 in the range 1-100 mM
100
1-Tetradecanol
Homo sapiens
IC50 above 100 mM
0.0043
2,6-dichloro-4-(1,2,3,4-tetrahydroisoquinolin-5-yl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
Trypanosoma brucei
-
pH 7.4, 22°C
0.000002
2,6-dichloro-4-(2-piperazin-1-ylpyridin-4-yl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)-benzenesulfonamide
Trypanosoma brucei
-
pH 7.4, 22°C
0.049
2,6-dichloro-4-(isoquinolin-5-yl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
Trypanosoma brucei
-
pH 7.4, 22°C
0.000012
2,6-dichloro-4-[2-(4-methylpiperazin-1-yl)pyridin-4-yl]-N-(1,5-dimethyl-3-isobutyl-1H-pyrazol-4-yl)benzenesulfonamide
Aspergillus fumigatus
pH not specified in the publication, temperature not specified in the publication
0.0000137 - 0.000023
2,6-dichloro-4-[2-(piperazin-1-yl)pyridin-4-yl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
0.00029
2,6-dichloro-4-[6-(piperazin-1-yl)pyridin-3-yl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
Trypanosoma brucei
-
pH 7.4, 22°C
0.001
2,6-dichloro-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
Trypanosoma brucei
-
pH 7.4, 22°C
0.01
2-(acetylamino)-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: above 0.01 mM
0.01
2-(benzylamino)-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: above 0.01 mM
0.01
2-amino-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: above 0.01 mM
1
2-dodecylglycidoyl-S-CoA
Homo sapiens
IC50 below 1 mM
0.0033
2-oxo-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide
Trypanosoma brucei
-
pH 7.4, 22°C
0.000046
2-[(2-methylpropanoyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: 0.000046 mM
0.000028
2-[(cyclobutylcarbonyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: 0.000028 mM
0.0000344
2-[(cyclohexanecarbonyl)amino]-N-[(2-naphthylmethyl)amino]ethyl-benzothiazole-6-carboxamide
Candida albicans
IC50: 0.0000344 mM
0.1
2-[(cyclohexylcarbonyl)amino]-1-methyl-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1H-benzimidazole-5-carboxamide
Candida albicans
IC50: above 0.1 mM
0.1
2-[(cyclohexylcarbonyl)amino]-1-methyl-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1H-benzimidazole-6-carboxamide
Candida albicans
IC50: above 0.1 mM
0.0019
2-[(cyclohexylcarbonyl)amino]-N-(3-[[(naphthalen-2-ylmethyl)amino]methyl]benzyl)-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: 0.0019 mM
0.1
2-[(cyclohexylcarbonyl)amino]-N-(4-[[(naphthalen-2-ylmethyl)amino]methyl]benzyl)-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: above 0.1 mM
0.0068
2-[(cyclohexylcarbonyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-5-carboxamide
Candida albicans
IC50: 0.0068 mM
0.001
2-[(cyclohexylcarbonyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-7-carboxamide
Candida albicans
IC50: 0.001 mM
0.0011
2-[(cyclohexylcarbonyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzoxazole-5-carboxamide
Candida albicans
IC50: 0.0011 mM
0.00029
2-[(cyclohexylcarbonyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzoxazole-6-carboxamide
Candida albicans
IC50: 0.00029 mM
0.00011
2-[(cyclohexylcarbonyl)amino]-N-[3-[(naphthalen-2-ylmethyl)amino]propyl]-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: 0.00011 mM
0.000074
2-[(cyclohexylcarbonyl)amino]-N-[4-[(naphthalen-2-ylmethyl)amino]butyl]-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: 0.000074 mM
0.0003
2-[(cyclohexylcarbonyl)amino]-N-[5-[(naphthalen-2-ylmethyl)amino]pentyl]-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: 0.0003 mM
0.001
2-[(cyclohexylmethyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: above 0.001 mM
0.000023
2-[(cyclopentylcarbonyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: 0.000023 mM
0.00031
2-[[(2,5-dimethoxyphenyl)carbonyl]amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: 0.00031 mM
0.01
2-[[(2-chloropyridin-3-yl)carbonyl]amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: above 0.01 mM
0.01
2-[[(3,4-dichlorophenyl)carbonyl]amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: above 0.01 mM
0.01
2-[[(4-chlorophenyl)carbonyl]amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: above 0.01 mM
0.0009
3',5'-dichloro-4'-[(1,3,5-trimethyl-1H-pyrazol-4-yl)sulfamoyl]biphenyl-3-carboxamide
Trypanosoma brucei
-
pH 7.4, 22°C
0.000005
3,5-dichloro-3'-[(4-methylpiperazin-1-yl)methyl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)biphenyl-4-sulfonamide
Trypanosoma brucei
-
pH 7.4, 22°C
0.00002
3,5-dichloro-3'-[(diethylamino)methyl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)biphenyl-4-sulfonamide
Trypanosoma brucei
-
pH 7.4, 22°C
0.0012
3,5-dichloro-4'-[(4-methylpiperazin-1-yl)methyl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)biphenyl-4-sulfonamide
Trypanosoma brucei
-
pH 7.4, 22°C
0.011
3,5-dichloro-4'-[(diethylamino)methyl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)biphenyl-4-sulfonamide
Trypanosoma brucei
-
pH 7.4, 22°C
0.028
3-cyano-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
Trypanosoma brucei
-
pH 7.4, 22°C
100
3-tetradecyn-1-ol
Homo sapiens
IC50 above 100 mM
0.0048
4-(1H-pyrazol-1-yl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
Trypanosoma brucei
-
pH 7.4, 22°C
0.000034
4-bromo-2,6-dichloro-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)-benzenesulfonamide
Trypanosoma brucei
-
pH 7.4, 22°C
0.1
4-bromo-N-[(1,3,5-trimethyl-1H-pyrazol-4-yl)methyl]benzenesulfonamide
Trypanosoma brucei
-
above, pH 7.4, 22°C
0.032
4-cyano-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
Trypanosoma brucei
-
pH 7.4, 22°C
0.1
4-[(4-bromophenoxy)methyl]-1,3,5-trimethyl-1H-pyrazole
Trypanosoma brucei
-
above, pH 7.4, 22°C
0.042
4-[[(4-bromophenyl)sulfonyl]methyl]-1,3,5-trimethyl-1H-pyrazole
Trypanosoma brucei
-
pH 7.4, 22°C
0.012
6-(2-methyl-1,3-thiazol-4-yl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
Trypanosoma brucei
-
pH 7.4, 22°C
0.0013
6-(benzylamino)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
Trypanosoma brucei
-
pH 7.4, 22°C
0.0019
6-(morpholin-4-yl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
Trypanosoma brucei
-
pH 7.4, 22°C
0.001
6-([2-[4-(propan-2-yl)piperazin-1-yl]ethyl]amino)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
Trypanosoma brucei
-
pH 7.4, 22°C
0.026
6-chloro-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
Trypanosoma brucei
-
pH 7.4, 22°C
0.00033
6-[(1H-indol-5-ylmethyl)amino]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
Trypanosoma brucei
-
pH 7.4, 22°C
0.00014
6-[2-(4-methylpiperazin-1-yl)ethylamino]pyridine-3-sulfonic acid (1,3,5-trimethyl-1H-pyrazol-4-yl)amide
Trypanosoma brucei
-
pH 7.4, 22°C
0.00003
6-[3-(piperazin-1-yl)piperidin-1-yl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
Trypanosoma brucei
-
pH 7.4, 22°C
0.00011
6-[3-(piperazin-1-yl)pyrrolidin-1-yl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
Trypanosoma brucei
-
pH 7.4, 22°C
0.00003
6-[[2-(1-methylpiperidin-4-yl)ethyl]amino]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
Trypanosoma brucei
-
pH 7.4, 22°C
0.0013
6-[[2-(1H-imidazol-1-yl)ethyl]amino]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
Trypanosoma brucei
-
pH 7.4, 22°C
0.01
6-[[2-(4-benzylpiperazin-1-yl)ethyl]amino]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
Trypanosoma brucei
-
pH 7.4, 22°C
0.00011
6-[[2-(4-methylpiperazin-1-yl)ethyl]amino]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
Trypanosoma brucei
-
pH 7.4, 22°C
0.001
6-[[2-(4-phenylpiperazin-1-yl)ethyl]amino]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
Trypanosoma brucei
-
pH 7.4, 22°C
0.038
6-[[2-(morpholin-4-yl)ethyl]amino]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
Trypanosoma brucei
-
pH 7.4, 22°C
0.001
6-[[2-(piperazin-1-yl)ethyl]amino]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
Trypanosoma brucei
-
pH 7.4, 22°C
0.014
6-[[2-(piperidin-1-yl)ethyl]amino]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
Trypanosoma brucei
-
pH 7.4, 22°C
0.0021
6-[[3-(dimethylamino)propyl]amino]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
Trypanosoma brucei
-
pH 7.4, 22°C
0.00036
6-[[4-[(dimethylamino)methyl]benzyl](methyl)amino]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
Trypanosoma brucei
-
pH 7.4, 22°C
0.00046
CP-014553
Trypanosoma brucei
IC50: 460 nM
0.00025
CP-030890-27
Trypanosoma brucei
IC50: 250 nM
1
lauric acid
Homo sapiens
IC50 below 1 mM
1
myristelaidic acid
Homo sapiens
IC50 below 1 mM
1 - 100
myristic acid
Homo sapiens
IC50 in the range 1-100 mM
1
myristoleic acid
Homo sapiens
IC50 below 1 mM
1
N(2-S-CoA-tetradecanoyl)glycinamide
Homo sapiens
IC50 below 1 mM
0.012
N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
Trypanosoma brucei
-
pH 7.4, 22°C
0.000024 - 0.0243
N-(10-aminodecanoyl)-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide
0.000349 - 0.000513
N-(11-aminoundecanoyl)-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide
0.1
N-(4-bromobenzyl)-1,3,5-trimethyl-1H-pyrazol-4-amine
Trypanosoma brucei
-
above, pH 7.4, 22°C
0.1
N-(4-bromophenyl)-1,3,5-trimethyl-1H-pyrazole-4-carboxamide
Trypanosoma brucei
-
above, pH 7.4, 22°C
0.1
N-(4-bromophenyl)-1,3,5-trimethyl-1H-pyrazole-4-sulfonamide
Trypanosoma brucei
-
above, pH 7.4, 22°C
0.00016
N-(6-[[N-(biphenyl-4-ylmethyl)-b-alanyl]amino]-1,3-benzothiazol-2-yl)cyclopentanecarboxamide
Candida albicans
IC50: 0.00016 mM
0.00018
N-(6-[[N-(naphthalen-2-ylmethyl)-b-alanyl]amino]-1,3-benzothiazol-2-yl)cyclohexanecarboxamide
Candida albicans
IC50: 0.00018 mM
0.0023
N-(6-[[N-(naphthalen-2-ylmethyl)glycyl]amino]-1,3-benzothiazol-2-yl)cyclohexanecarboxamide
Candida albicans
IC50: 0.0023 mM
0.000059
N-[2-chloro-5-[(3S,4R)-1-[4-(4-chlorophenyl)-3-hydroxybutanoyl]-4-(hydroxymethyl)pyrrolidin-3-yl]phenyl]-2-(4-fluorophenyl)acetamide
Leishmania donovani
pH not specified in the publication, temperature not specified in the publication
0.0000033
N-[2-[(2-methylpropanoyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
Candida albicans
IC50: 0.0000033 mM
0.0000023
N-[2-[(cyclobutylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
Candida albicans
IC50: 0.0000023 mM
0.0000081
N-[2-[(cyclohexylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
Candida albicans
IC50: 0.0000081 mM
0.0000012
N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
Candida albicans
IC50: 0.0000012 mM
0.00013
N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[[(4-phenylcyclohexa-1,5-dien-1-yl)methyl]amino]cyclohexanecarboxamide
Candida albicans
IC50: 0.00013 mM
0.0000024
N-[2-[(cyclopropylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
Candida albicans
IC50: 0.0000024 mM
0.01
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: above 0.01 mM
0.00013
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-(propanoylamino)-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: 0.00013 mM
0.01
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-([[4-(trifluoromethyl)phenyl]carbonyl]amino)-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: above 0.01 mM
0.00016
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-[(phenylcarbonyl)amino]-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: 0.00016 mM
0.00073
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-[(pyrazin-2-ylcarbonyl)amino]-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: 0.00073 mM
0.01
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-[(pyridin-2-ylcarbonyl)amino]-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: above 0.01 mM
0.01
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-[(pyridin-2-ylmethyl)amino]-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: above 0.01 mM
0.0028
N-[4-[(1,3,5-trimethyl-1H-pyrazol-4-yl)sulfamoyl]phenyl]acetamide
Trypanosoma brucei
-
pH 7.4, 22°C
0.0000016
N-[5-[(4R)-1-[(3R)-3-amino-4-(4-chlorophenyl)butanoyl]-4-(hydroxymethyl)pyrrolidin-3-yl]-2-chlorophenyl]-2-(4-fluorophenyl)acetamide
Leishmania donovani
pH not specified in the publication, temperature not specified in the publication
0.000065
N-[6-([3-[(naphthalen-2-ylmethyl)amino]azetidin-1-yl]carbonyl)-1,3-benzothiazol-2-yl]cyclohexanecarboxamide
Candida albicans
IC50: 0.000065 mM
0.00021
N-[6-([3-[(naphthalen-2-ylmethyl)amino]piperidin-1-yl]carbonyl)-1,3-benzothiazol-2-yl]cyclohexanecarboxamide
Candida albicans
IC50: 0.00021 mM
0.00019
N-[6-([3-[(naphthalen-2-ylmethyl)amino]pyrrolidin-1-yl]carbonyl)-1,3-benzothiazol-2-yl]cyclohexanecarboxamide
Candida albicans
IC50: 0.00019 mM
0.000015
N-[6-([4-[(naphthalen-2-ylmethyl)amino]butanoyl]amino)-1,3-benzothiazol-2-yl]cyclopentanecarboxamide
Candida albicans
IC50: 0.000015 mM
0.0005
N-[6-([4-[(naphthalen-2-ylmethyl)amino]piperidin-1-yl]carbonyl)-1,3-benzothiazol-2-yl]cyclohexanecarboxamide
Candida albicans
IC50: 0.0005 mM
0.000026
N-[6-[(4-[[(naphthalen-2-ylmethyl)amino]methyl]piperidin-1-yl)carbonyl]-1,3-benzothiazol-2-yl]cyclohexanecarboxamide
Candida albicans
IC50: 0.000026 mM
1 - 100
palmitic acid
Homo sapiens
IC50 in the range 1-100 mM
1
S-(2-bromotetradecanoyl)-CoA
Homo sapiens
IC50 below 1 mM
0.00006
S-(2-ketopentadecyl)-CoA
Homo sapiens
IC50: 0.00006 mM
0.0000687 - 0.0687
S-(2-oxo)pentadecyl-CoA
0.01
tert-butyl 4-[2-([5-[(1,3,5-trimethyl-1H-pyrazol-4-yl)sulfamoyl]pyridin-2-yl]amino)ethyl]piperazine-1-carboxylate
Trypanosoma brucei
-
pH 7.4, 22°C
0.01
tert-butyl [6-([2-[(naphthalen-2-ylmethyl)amino]ethyl]carbamoyl)-1,3-benzothiazol-2-yl]carbamate
Candida albicans
IC50: above 0.01 mM
100
tetradecyl trimethylammonium bromide
Homo sapiens
IC50 above 100 mM
100
tetradecyl triphenylphosphonium bromide
Homo sapiens
IC50 above 100 mM
0.000034
trans-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
Candida albicans
IC50: 0.000034 mM
additional information
additional information
-
0.00002
1-(4-(3,5-dichloro-4-(pyridin-2-ylmethoxy)phenyl)pyridin-2-yl)-piperazine
Trypanosoma brucei
-
pH 7.4, 22°C
0.0001
1-(4-(3,5-dichloro-4-(pyridin-2-ylmethoxy)phenyl)pyridin-2-yl)-piperazine
Trypanosoma brucei
-
pH 7.4, 22°C
0.0000137
2,6-dichloro-4-[2-(piperazin-1-yl)pyridin-4-yl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
Homo sapiens
-
pH 7.9-8.0, 25°C, isozyme NMT1
0.0000144
2,6-dichloro-4-[2-(piperazin-1-yl)pyridin-4-yl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
Homo sapiens
-
pH 7.9-8.0, 25°C, isozyme NMT2
0.000023
2,6-dichloro-4-[2-(piperazin-1-yl)pyridin-4-yl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
Aspergillus fumigatus
pH not specified in the publication, temperature not specified in the publication
0.000024
N-(10-aminodecanoyl)-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide
Leishmania donovani
pH not specified in the publication, temperature not specified in the publication
0.00006
N-(10-aminodecanoyl)-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00068
N-(10-aminodecanoyl)-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide
Plasmodium vivax
pH not specified in the publication, temperature not specified in the publication
0.0243
N-(10-aminodecanoyl)-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide
Plasmodium falciparum
-
pH not specified in the publication, temperature not specified in the publication
0.000349
N-(11-aminoundecanoyl)-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide
Homo sapiens
-
pH 7.9-8.0, 25°C, isozyme NMT1
0.000513
N-(11-aminoundecanoyl)-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide
Homo sapiens
-
pH 7.9-8.0, 25°C, isozyme NMT2
0.0000687
S-(2-oxo)pentadecyl-CoA
Leishmania donovani
-
0.0687
S-(2-oxo)pentadecyl-CoA
Leishmania donovani
pH 7.4, 37°C, recombinant enzyme
additional information
additional information
Homo sapiens
IC50 values of different inhibitors, overview
-
additional information
additional information
Homo sapiens
IC50 values of different inhibitors, overview
-
additional information
additional information
Homo sapiens
-
IC50 values of different inhibitors, overview
-
additional information
additional information
Leishmania donovani
IC50 values of different inhibitors, overview
-
additional information
additional information
Leishmania donovani
-
IC50 values of different inhibitors, overview
-
additional information
additional information
Plasmodium falciparum
IC50 values of different inhibitors, overview
-
additional information
additional information
Plasmodium falciparum
-
IC50 values of different inhibitors, overview
-
additional information
additional information
Trypanosoma brucei
IC50 values of different inhibitors, overview
-
additional information
additional information
Trypanosoma brucei
-
IC50 values of different inhibitors, overview
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.